

# CARDIOVASCULAR RESEARCH

2008 - 2009





# TABLE OF CONTENTS

## ROCHESTER, MINNESOTA

### INTEGRATED PHYSIOLOGY

Virend K. Somers, MD, DPhil.....	6
Bruce D. Johnson, PhD.....	7
Juan Carlos Romero, MD.....	8
Lilach O. Lerman, MD, PhD.....	9

### PEDIATRICS/CONGENITAL HEART DISEASE

David J. Driscoll, MD.....	10
Benjamin W. Eidem, MD.....	11
Frank Cetta, MD.....	12
Allison K. Cabalka, MD.....	13
Patrick W. O'Leary, MD.....	14

### CARDIAC SURGERY

Christopher G.A. McGregor, MB, FRCS.....	15
Harold M. Burkhart, MD.....	16
Thoralf M. Sundt III, MD.....	17
Joseph A. Dearani, MD.....	18
Richard C. Daly, MD.....	19
Rakesh M. Suri, MD.....	20
Soon J. Park, MD.....	21

### BIOMARKERS/OUTCOMES

Iftikhar J. Kullo, MD.....	22
Véronique L. Roger, MD, MPH.....	23
Allan S. Jaffe, MD.....	24
Henry H. Ting, MD, MBA.....	25

### PREVENTION/WOMEN'S HEALTH

Gerald T. Gau, MD.....	26
Francisco Lopez-Jimenez, MD, MSc.....	27
Sharonne N. Hayes, MD.....	28
Thomas G. Allison, PhD, MPH.....	29
Randal J. Thomas, MD, MS.....	30
Sharon L. Mulvagh, MD.....	31

### ELECTROPHYSIOLOGY

Hon-Chi Lee, MD, PhD.....	32
Michael J. Ackerman, MD, PhD.....	33
Win-Kuang Shen, MD.....	34
Teresa S. Tsang, MD.....	35
Andre Terzic, MD, PhD.....	36
Timothy M. Olson, MD.....	37
Douglas L. Packer, MD.....	38
Naser M. Ammash, MD.....	39

### VASCULAR BIOLOGY/CORONARY ARTERY DISEASE

Robert D. Simari, MD.....	40
Birgit Kantor, MD.....	41
Frank V. Brozovich, MD, PhD.....	42
Charanjit S. Rihal, MD, MBA.....	43
David R. Holmes, Jr, MD.....	44
Abhiram Prasad, MD.....	45
Patricia J. M. Best, MD.....	46
Amir Lerman, MD.....	47
Martin G. Rodriguez-Porcel, MD.....	48
Gurpreet S. Sandhu, MD, PhD.....	49

### CARDIOMYOPATHY AND HEART FAILURE

Garvan C. Kane, MD, PhD.....	50
Leslie T. Cooper, MD.....	51
Rick A. Nishimura, MD.....	52
Steve R. Ommen, MD.....	53

Xiaolei Xu, PhD.....	54
Sudhir S. Kushwaha, MD.....	55
Horng H. Chen, MB, BCh.....	56
Barry A. Borlaug, MD.....	57
Lyle J. Olson, MD.....	58
John C. Burnett, Jr, MD.....	59
Margaret M. Redfield, MD.....	60
Robert P. Frantz, MD.....	61
Carmen M. Terzic, MD, PhD.....	62
Richard J. L. Rodeheffer, MD.....	63

### IMAGING

Panithaya Chareonthaitawee, MD.....	64
Raymond J. Gibbons, MD.....	65
Jae K. Oh, MD.....	66
Patricia A. Pellikka, MD.....	67
J. Wells Askew, MD.....	68
Hector R. Villarraga, MD.....	69
Todd D. Miller, MD.....	70

## PHOENIX/SCOTTSDALE, ARIZONA

### ELECTROPHYSIOLOGY

Arshad Jahangir, MD.....	72
Komandoor Srivathsan, MD, Gregory T. Altemose, MD, and Luis R.P. Scott, MD.....	73

### IMAGING

Christopher P. Appleton, MD.....	74
Marek Belohlavek, MD, PhD.....	75
Krishnaswamy Chandrasekaran, MD.....	76
Bijoy K. Khandheria, MD.....	77
Steven J. Lester, MD.....	78
A. Jamil Tajik, MD.....	79
Partho P. Sengupta, MD.....	80

### PREVENTION/WOMEN'S HEALTH

Susan Wilansky, MD.....	81
Farouk Mookadam, MD.....	82

### HEART FAILURE

Robert L. Scott, MD.....	83
--------------------------	----

### VASCULAR BIOLOGY/CORONARY ARTERY DISEASE

F. David Fortuin, MD.....	84
---------------------------	----

### VALVULAR HEART DISEASE

Hari P. Chaliki, MD.....	85
--------------------------	----

### CARDIAC SURGERY

Francisco A. Arabia, MD.....	86
R. Todd Hurst, MD.....	87

## JACKSONVILLE, FLORIDA

### ELECTROPHYSIOLOGY

K. L. Venkatachalam, MD.....	89
Fred M. Kusumoto, MD.....	90

### HEART FAILURE

Jeffrey D. Hosenpud, MD.....	91
Joseph L. Blackshear, MD.....	92
Mohamad H. Yamani, MD.....	93

### IMAGING

Thomas C. Gerber, MD, PhD.....	94
--------------------------------	----



Dear Colleague:

On behalf of the Division of Cardiovascular Diseases and our colleagues in the Divisions of Cardiovascular Surgery and Pediatric Cardiology, I would like to take this opportunity to welcome you to Mayo Clinic Rochester, Mayo Clinic Arizona, and Mayo Clinic Florida, Cardiovascular Research 2008-2009. The mission of Cardiovascular Research at Mayo Clinic is to understand, optimally treat, ultimately predict, and cure cardiovascular disease. The Cardiovascular Research Committees consist of well-integrated, broadly defined groups of investigators with particular strengths in ischemic heart disease, heart failure, imaging, and arrhythmogenesis. This booklet provides a glimpse into this widely varied research community that extends from basic molecular sciences to clinical epidemiology.


The community represented in this booklet is actively involved in education of undergraduates, medical students, graduate students, residents, and postdoctoral fellows. The groups host visiting scientists from all over the world. If you are interested in contacting any of the investigators whose work is described in this booklet, please do not hesitate to use the contact information provided on the back cover.

Sincerely,


A handwritten signature in black ink that reads "Robert D. Simari". The signature is written in a cursive, professional style.

Robert D. Simari, MD  
Professor of Medicine  
Vice Chair for Cardiovascular Research  
Mayo Clinic Rochester


**Total Cardiovascular Research Funding by Source**



**Total Cardiovascular Research Funding by Year**



**Publications by Mayo Clinic Cardiovascular Staff**





In August 2007, the Judd Leighton Cardiovascular Research Laboratories were dedicated on the fourth and fifth floors of the Vincent A. Stabile Building. These state-of-the-art research laboratories are used by basic and translational cardiovascular scientists. Judd Leighton's relationship with Mayo Clinic encompassed close friendships and a strong philanthropic spirit that continues through his foundation.




Robert Simari, MD, vice chair for cardiovascular research (right), and Alexander Schirger, MD (second from right), and members of the Judd Leighton Foundation board tour new laboratory facilities.

A blue-tinted close-up photograph of a glass bottle, likely a perfume or medicine bottle, with a mechanical stopper. The bottle is the central focus, with its facets and curves highlighted by the lighting. The stopper is a complex, multi-tiered mechanical device. The background is a soft, out-of-focus blue.

R O C H E S T E R

**M** I N N E S O T A



## VIREND K. SOMERS, MD, DPHIL

Dr Somers's research interests relate to the links between sleep disorders, obesity, and cardiovascular disease. His research techniques include population studies, patient-oriented research, and molecular studies of disease mechanisms. Ongoing studies are evaluating the inflammatory, vascular, metabolic, and molecular consequences of fat gain in healthy individuals; identifying the mechanisms by which sleep apnea and sleep deprivation may induce cardiac and vascular events; exploring the links between sleep and the early morning surge in cardiovascular and cerebrovascular events; and defining the mechanisms leading to increased cardiovascular risk in National Football League players and other professional athletes.

Funding for his research program is provided by several grants from the National Institutes of Health as well as predoctoral and postdoctoral awards from the American Heart Association.

### SELECTED PUBLICATIONS

Singh P, Hoffmann M, Wolk R, Shamsuzzaman ASM, Somers VK. Leptin induces C-reactive protein expression in vascular endothelial cells. *Arterioscler Thromb Vasc Biol* 2007;27:e302-e307.

Gami AS, Howard DE, Olson EJ, Somers VK. Altered day-night pattern of sudden cardiac death in patients with obstructive sleep apnea. *N Engl J Med* 2005;352:1206-1214.

Somers VK. Sleep: a new cardiovascular frontier. *N Engl J Med* 2005;353:2070-2073.


Kapa S, Somers VK. Cardiovascular manifestation of autonomic disorders. In: Libby P, Bonow R, Mann DL, Zipes DP, editors. *Braunwald's heart disease: a textbook of cardiovascular medicine*. 8th edition. Philadelphia, PA: Saunders; 2007.

Kara T, Wolk R, Somers VK. Sleep apnea and cardiac disease. In: Murphy JG, Lloyd MA, editors. *Mayo Clinic cardiology: concise textbook*. 3rd edition. Murphy JG, Lloyd MA, editors. Rochester, MN: Mayo Clinic Scientific Press, Informa Healthcare; 2007. pp. 1035-1042.



## BRUCE D. JOHNSON, PHD

Dr Johnson's laboratory is focused on human integrative and applied physiology. Recent studies have centered around the impact of altered cardiovascular function associated with heart failure on the respiratory system. In particular, the project has included studying heart failure-related changes in lung mechanics, gas exchange, and ventilatory control and the impact on functional capacity. Novel methods have been developed to assess cardiac output, to quantify alveolar-capillary recruitment, and to measure pulmonary and airway blood flow noninvasively. His laboratory also has a strong interest in human adaptation to hypoxia-altitude and possible synergies with disease. He is funded by grants from the National Institutes of Health, the National Science Foundation, and the American Heart Association.



### SELECTED PUBLICATIONS

Snyder EM, Beck KC, Dietz NM, Eisenach JH, Joyner MJ, Turner ST, Johnson BD. Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. *J Physiol* 2006;571(Pt 1):121-130.

Olson TP, Beck KC, Johnson JB, Johnson BD. Competition for intrathoracic space reduces lung capacity in patients with chronic heart failure: a radiographic study. *Chest* 2006;130:164-171.

Olson TP, Snyder EM, Johnson BD. Exercise-disordered breathing in chronic heart failure. *Exerc Sport Sci Rev* 2006;34:194-201.

Snyder EM, Beck KC, Hulsebus ML, Breen JF, Hoffman EA, Johnson BD. Short term hypoxic exposure at rest and during exercise reduces lung water in healthy humans. *J Appl Physiol* 2006;101:1623-1632.

Olson TP, Frantz RP, Snyder EM, O'Malley KA, Beck KC, Johnson BD. Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. *Am Heart J* 2007;153:104.e1-104.e7.



## JUAN CARLOS ROMERO, MD

Dr Romero's research covers 2 areas:

- To understand the renal mechanisms responsible for the control of blood pressure. Specific emphasis is placed on the role of the renin-angiotensin system, oxidative stress, and sodium metabolism.
- To develop a noninvasive system based on imaging provided by 3-dimensional computed tomography with high temporal resolution or magnetic resonance to evaluate renal function. This has been done in diseases that affect the kidney such as renovascular hypertension and obstructive nephropathies.



### SELECTED PUBLICATIONS

Daghini E, Juillard L, Haas JA, Krier JD, Romero JC, Lerman LO. Comparison of mathematic models for assessment of glomerular filtration rate with electron beam CT in pigs. *Radiology* 2007;242:417-424.

Juillard L, Lerman LO, Kruger DG, Haas JA, Rucker BC, Polzin JA, Riederer SJ, Romero JC. Blood oxygen level-dependent measurement of acute intrarenal ischemia. *Kidney Int* 2004;65:944-950.

Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin induced hypertension. *Am J Physiol Reg* 2003;284:R893-R912.

Bentley MD, Ortiz MC, Ritman EL, Romero JC. The use of microcomputed tomography to study microvasculature in small rodents. *Am J Physiol* 2002;282:R1267-R1279.

Romero JC, Lerman LO. Novel noninvasive techniques for studying renal function in man. *Semin Nephrol* 2000;20:456-462.

## LILACH O. LERMAN, MD, PhD

Dr Lerman's research involves development and application of basic science techniques to study renal and cardiovascular physiology and pathophysiology in both animal and human models. High-resolution imaging methods are applied for exploration of physiologic processes and of adaptive responses to cardiovascular disease, such as hypertension, ischemia, hypercholesterolemia, and early atherosclerosis. Disease mechanisms are subsequently investigated using molecular biology and cell culture techniques, and potential therapeutic targets are identified using novel interventions, including drugs, revascularization, and progenitor cell delivery. The research has been supported by grants from the National Institutes of Health and the American Heart Association.



### SELECTED PUBLICATIONS


Zhu XY, Daghini E, Chade AR, Napoli C, Ritman EL, Lerman A, Lerman LO. Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. *J Am Soc Nephrol* 2007;18:1209-1217.

Zhu XY, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, Lerman LO. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. *Arterioscler Thromb Vasc Biol* 2006;26:1746-1752.

Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. *FASEB J* 2006;20:1706-1708.

Chade AR, Mushin OP, Xhu X, Rodriguez-Porcel M, Grande JP, Textor SC, Lerman A, Lerman LO. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. *Hypertension* 2005;46:772-779.

Zhu X, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. *Circulation* 2004;109:2109-2015.



## DAVID J. DRISCOLL, MD

Dr Driscoll pursues epidemiological and outcome analysis of pediatric cardiac disease. Using the Mayo Clinic database, he is able to evaluate the usefulness of various diagnostic procedures and efficacy of treatment. Currently he is analyzing long-term outcomes of 538 patients who have had surgery for Ebstein anomaly.

Dr Driscoll is also completing a meta-analysis of the effect of pectus excavatum repair on short- and long-term cardiopulmonary function. He continues to collaborate in studying the genetic basis of vascular malformations.

### SELECTED PUBLICATIONS

Vyas H, Driscoll D, Cetta F, Loftus C, Connolly H. Gastrointestinal bleeding and protein-losing enteropathy after the Fontan operation: cause and effect or coincidence? *Am J Cardiol* 2006;98:666-667.

Bartz PJ, Driscoll DJ, Dearani JA, Puga FJ, Danielson GK, O'Leary PW, Earing MG, Warnes CA, Hodge DO, Cetta F. Early and late results of the modified Fontan operation for heterotaxy syndrome. *J Am Coll Cardiol* 2006;48:2301-2305.

Delis KT, Gloviczki P, Wennberg P, Rooke T, Driscoll DJ. Hemodynamic impairment, venous segmental disease (VSDS) and clinical severity (VCSS) scoring in limbs with Klippel-Trenaunay syndrome. *J Vasc Surg* 2007;45:561-567.

Boston U, Dearani J, O'Leary P, Driscoll D, Danielson G. Tricuspid valve repair for Ebstein's anomaly in young children: a 30 year experience. *Ann Thorac Surg* 2006;81:690-695.

Husmann DA, Rathburn SR, Driscoll DJ. Klippel-Trenaunay syndrome: incidence and treatment of genitourinary sequelae. *J Urol* 2007;177:1244-1249.

Driscoll DJ. Socrates, epistemology, and pediatric cardiology, or should doctors think like lawyers? *Congenit Heart Dis* 2007;2:220-223.



## BENJAMIN W. EIDEM, MD

Tissue Doppler and strain rate imaging are novel echocardiographic techniques that enable quantitative evaluation of the motion and deformation of the myocardium. Dr Eidem's research interests have focused on the application of these exciting new advances in noninvasive imaging to the evaluation of ventricular function in fetuses, children, and adults with congenital heart disease. In particular, his research has focused on the impact of altered geometry and loading conditions on these echocardiographic parameters in both preoperative and postoperative settings. In addition, the impact of medical, interventional, and surgical therapies on short- and long-term ventricular performance has also been an important area of ongoing research in congenital heart disease.



### SELECTED PUBLICATIONS

Eidem BW, McMahon CJ, Cohen RR, Wu J, Finkelshteyn I, Kovalchin JP, Ayres NA, Bezold LI, EO Smith, Pignatelli RH. Impact of cardiac growth on Doppler tissue imaging velocities: a study in normal children. *J Am Soc Echocardiogr* 2004;17:212-221.

Eidem BW, McMahon CJ, Ayres NA, Kovalchin JP, Denfield SJ, Altman CA, Bezold LI, Pignatelli RH. Clinical impact of altered left ventricular loading conditions on Doppler tissue imaging velocities: a study in congenital heart disease. *J Am Soc Echocardiogr* 2005;18:830-838.

McMahon CJ, Nagueh SF, Pignatelli RH, Dreyer WJ, Denfield S, Clunie S, Bezold LI, Hayes M, Towbin JA, Eidem BW. Characterization of left ventricular diastolic function using tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. *Circulation* 2004;109:1756-1762.

McMahon CJ, Pignatelli RH, Nagueh SF, Jeffries JL, Valdes SO, Kovalchin JP, Kim JJ, Dimas V, Dreyer WJ, Denfield SD, Clunie S, Bowles NE, Towbin JA, Eidem BW. Left ventricular non-compaction cardiomyopathy in children: characterisation of clinical status using tissue Doppler-derived indices of left ventricular diastolic relaxation. *Heart* 2007;93:676-681. Erratum in: *Heart*. 2007;93:984.

Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA. Genetic predictors and reverse remodeling of dilated cardiomyopathy in muscular dystrophy. *Circulation* 2005; 112: 2799-2804.



## FRANK CETTA, MD

Dr Cetta has many clinical research interests in the field of pediatric cardiology. Particular areas of interest include

- placement of intra- and extra-cardiac closure devices
- heparin-induced thrombocytopenia in congenital heart disease
- clinical outcomes of adults with congenital heart disease
- advanced echocardiography in congenital heart disease
- long-term follow-up of patients with congenital heart disease after Fontan operation

### SELECTED PUBLICATIONS

Porcelli R, Moskowitz BC, Cetta F, Graham LC, Eidem BW, Godwin JE, Prechel MM, Walenga JM. Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases. *Tex Heart Inst J* 2003;30:58-61.

Sherman JM, Hagler DJ, Cetta F. Thrombosis after septal closure device placement: a review of the current literature. *Catheter Cardiovasc Interv* 2004;63:486-489.

Earing MG, Cetta F, Driscoll DJ, Mair DD, Hodge DO, Dearani JA, Puga FJ, Danielson GK, O'Leary PW. Long-term results of the Fontan operation for double-inlet left ventricle. *Am J Cardiol* 2005;96:291-298.

Bartz PJ, Cetta F, Cabalka AK, Reeder GS, Squarcia U, Agnetti A, Aurier E, Carano N, Tachana B, Hagler DJ. Paradoxical emboli in children and young adults: role of atrial septal defect and patent foramen ovale device closure. *Mayo Clin Proc* 2006;81:615-618.

Bartz PJ, Driscoll DJ, Dearani JA, Puga FJ, Danielson GK, O'Leary PW, Earing MG, Warnes CA, Hodge DO, Cetta F. Early and late results of the modified Fontan operation for heterotaxy syndrome: 30 years of experience in 142 patients. *J Am Coll Cardiol* 2006;48:2301-2305.



## ALLISON K. CABALKA, MD

Dr Cabalka leads the congenital catheterization laboratory research efforts. Her interests primarily involve use of cutting-edge interventional catheterization therapy for children and adults with congenital heart disease. She also is active in the congenital echocardiography laboratory and complements her work in the catheterization laboratory with use of intracardiac echocardiography. Dr Cabalka is a champion for international humanitarian efforts to deliver quality pediatric cardiology care to emerging nations.



### SELECTED PUBLICATIONS

Bartz PJ, Cetta F, Cabalka AK, Reeder GS, Squarcia U, Agnetti A, Aurier E, Carano N, Tachana B, Hagler DJ. Paradoxical emboli in children and young adults: role of atrial septal defect and patent foramen ovale device closure. *Mayo Clin Proc* 2006; 81:615-618.

Bos JM, Hagler DJ, Silvilairat S, Cabalka A, O'Leary P, Daniels O, Miller FA, Abraham TP. Right ventricular function in asymptomatic individuals with a systemic right ventricle. *J Am Soc Echocardiogr* 2006;19:1033-1037.

Sorajja P, Cabalka AK, Hagler DJ, Reeder GS, Chandrasekaran K, Cetta F, Rihal CS. Successful percutaneous repair of perivalvular prosthetic regurgitation. *Catheter Cardiovasc Interv* 2007;70:815-823.

Vyas H, Driscoll DJ, Cabalka AK, Cetta F, Hagler DJ. Results of transcatheter Fontan fenestration to treat protein losing enteropathy. *Catheter Cardiovasc Interv* 2007;69:584-589.

Menon SC, O'Leary PW, Wright GB, Rios R, MacLellan-Tobert SG, Cabalka AK. Fetal and neonatal presentation of noncompacted ventricular myocardium: expanding the clinical spectrum. *J Am Soc Echocardiogr* 2007;20:1344-1350.



## PATRICK W. O'LEARY, MD

Dr O'Leary's current research efforts are focused on improving understanding of the following concepts:

- The relationships between Doppler hemodynamics and clinical parameters and their relationship to pediatric patient outcomes.
- The anatomy of complex congenital cardiac malformations using multimodality imaging (including live 3-D echocardiography and intraoperative transesophageal echocardiography).
- Noninvasive assessment of myocardial systolic and diastolic function, with emphasis on the correct ventricle in patients with congenital cardiac malformations. Efforts in this area also involve correlation with the catheterization laboratory and cardiac magnetic resonance imaging center. Areas of special interest include myocardial deformation imaging (strain and strain rate evaluation) and retrospective studies aimed at outlining echocardiographic parameters that may predict patient outcomes.

### SELECTED PUBLICATIONS

Quinonez LG, Dearani JA, Puga FJ, O'Leary PW, Driscoll DJ, Connolly HM, Danielson GK. Results of the 1.5-ventricle repair for Ebstein anomaly and the failing right ventricle. *J Thorac Cardiovasc Surg* 2007;133:1303-1310.

Dearani JA, O'Leary PW, Danielson GK. Surgical treatment of Ebstein's malformation: state of the art in 2006. *Cardiol Young* 2006;16 (Suppl 3):12-20.

Martinez RM, O'Leary PW, Anderson RH. Anatomy and echocardiography of the normal and abnormal tricuspid valve. *Cardiol Young* 2006;16 (Suppl 3):4-11.

Bartz PJ, Driscoll DJ, Dearani JA, Puga FJ, Danielson GK, O'Leary PW, Earing MG, Warnes CA, Hodge DO, Cetta F. Early and late results of the modified Fontan operation for heterotaxy syndrome: 30 years of experience in 142 patients. *J Am Coll Cardiol* 2006;48:2301-2305.

Boston US, Dearani JA, O'Leary PW, Driscoll DJ, Danielson GK. Tricuspid valve repair for Ebstein's anomaly in young children: a 30-year experience. *Ann Thorac Surg* 2006;81:690-696.





## CHRISTOPHER G.A. MCGREGOR, MB, FRCS

One potential approach to address the donor shortage is xenotransplantation, which involves transplanting living organs from one species to another. The idea of conducting animal-to-human transplants is not a new one. Indeed, xenotransplantation has been tried at various times during the past 95 years. Recent scientific study has revealed that there exist specific molecular hurdles to carrying out pig-to-human xenografts and that these hurdles can be addressed in a definitive manner by the genetic engineering of animals. The success of this endeavor has stimulated the imagination of many in the field of transplantation. As well as organs, such as the heart and kidney, genetically altered animals could provide cells, for example, for the treatment of diabetes and other diseases and tissues for orthopedic (ligament and bone) and cardiac surgical (heart valves) applications.

Research studies in Dr McGregor's laboratory include

- Genetic Engineering Research. As part of the xenotransplantation research program, he has been studying the human immune system and genetically engineering pigs so that their organs do not trigger the standard human immune response that would destroy them when transplanted. Human transgenes have been added to the pig genome as well as the knocking out of specific pig genes that lead to animal organ rejection.
- Preclinical Research. Mayo Clinic transplant scientists and physicians are studying pig cardiac xenotransplantation using genetically altered pig donors. Studies of orthopedic and cardiac surgical applications of xenotransplantation are also being pursued.
- Immunosuppression and Rejection. A major focus in the xenotransplantation laboratory is optimization of immunosuppression following xenotransplantation, with specific studies on the pathophysiology of xenograft vascular rejection.

### SELECTED PUBLICATIONS

McGregor CGA, Teotia SS, Byrne GW, Michaels MG, Risdahl JM, Tazelaar HD, Walker RC, Logan JS. Cardiac xenotransplantation: progress towards the clinic. *Transplantation* 2004;78:1569-1575.

McGregor CGA, Davies WR, Oi K, Teotia SS, Schirmer JM, Risdahl JM, Tazelaar HD, Kremers WK, Walker RC, Byrne GW, Logan JS. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. *J Thorac Cardiovasc Surg* 2005;130:844-851.

Davila E, Byrne GW, LaBreche PT, McGregor HCJ, Schwab AK, Davies WR, Rao VP, Oi K, Tazelaar HD, Logan JS, McGregor CGA. T cell responses during pig-to-primate xenotransplantation. *Xenotransplantation* 2006;13:31-40.

Byrne GW, Davies WR, Oi K, Rao VP, Teotia SS, Ricci D, Tazelaar HD, Walker RC, Logan JS, McGregor CGA. Increased immunosuppression not anticoagulation extends cardiac xenograft survival. *Transplantation* 2006;82:1787-1791.

Rao VP, Miyagi N, Ricci D, Carlson SK, Morris JC 3rd, Federspiel MJ, Bailey KR, Russell SJ, McGregor CG. Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation. *Transplantation* 2007;84:1662-1666.



## HAROLD M. BURKHART, MD

Dr Burkhart's research interests focus on clinical aspects of congenital and pediatric cardiac surgery. Current projects include research on the surgical aspects of tetralogy of Fallot, coarctation of the aorta, Shone syndrome, and anomalous coronary arteries.

### SELECTED PUBLICATIONS

Burkhart HM, Dearani JA, Williams WG, Puga FJ, Mair DD, Ashburn DA, Webb GD, Danielson GK. Late results of palliative atrial switch for transposition, ventricular septal defect, and pulmonary vascular obstructive disease. *Ann Thorac Surg* 2004;77:464-468.

Fortuna RS, Ashburn DA, Carias De Oliveira N, Burkhart HM, Konstantinov IE, Coles JG, Smallhorn JF, Williams WG, Van Arsdell GS. Atrioventricular septal defects: effect of bridging leaflet division on early valve function. *Ann Thorac Surg* 2004;77:895-902.

De Oliveira NC, Ashburn DA, Khalid F, Burkhart HM, Adatia IT, Holtby HM, Williams WG, Van Arsdell GS. Prevention of early sudden circulatory collapse after the Norwood operation. *Circulation* 2004;110(11 Suppl 1):II133-II138.

Bagtharia R, Trivedi KR, Burkhart HM, Williams WG, Freedom RM, Van Arsdell GS, McCrindle BW. Outcomes for patients with an aortopulmonary window, and the impact of associated cardiovascular lesions. *Cardiol Young* 2004;14:473-480.

Burkhart HM, Ashburn DA, Konstantinov IE, De Oliveira NC, Benson L, Williams WG, Van Arsdell GS. Interdigitating arch reconstruction eliminates recurrent coarctation after the Norwood procedure. *J Thorac Cardiovasc Surg* 2005;130:61-65.

## THORALF M. SUNDT III, MD

Dr Sundt's main areas of investigation include bicuspid aortic valve disease and the role of human factors in cardiovascular surgery laboratory has projects under way addressing both the clinical behavior (phenomics) and genetic basis (genomics) of bicuspid aortic valve disease with a focus on aneurysmal disease. Drawing on the large Mayo Clinic surgical database and clinical experience, he is investigating the clinical behavior of this condition, including the natural history of the aorta and the risk of ultimate aortic dissection or rupture. Additionally, he is studying the basis of this condition with the ultimate translational goal of permitting genetically tailored surgical therapy. Furthermore, studies of individuals with a family history of bicuspid aortic valve disease have led Dr Sundt to identify novel areas of interest in the human genome as potential sites of the gene ultimately responsible for this common and clinically important condition.

Recognizing the critical role of primary research in laying the foundation for change in clinical practice, the cardiovascular surgery group has established an investigative program in human factors. The activities of this group are currently focused on the operating room itself, although the scope will expand to other areas of the hospital in the future. As part of the infrastructure for primary research on human factors and its impact on error management (error prevention, error detection, and error correction) in the cardiovascular surgical operating rooms, functioning cameras have been installed in one of the cardiovascular surgical operating rooms which permitting remote viewing of cases by staff without directly interfering with the team dynamics. This work has already led to important insights into team dynamics in this setting. Dr Sundt is also in the process of establishing interinstitutional collaborations regarding human factors to augment studies and facilitate the communication of findings with others.



### SELECTED PUBLICATIONS

ElBardissi AW, Wiegmann DA, Dearani JA, Daly RC, Sundt TM 3rd. Application of the human factors analysis and classification system methodology to the cardiovascular surgery operating room. *Ann Thorac Surg* 2007;83:1412-1419.

Sundt TM 3rd, Mora BN, Moon MR, Bailey MS, Pasque MK, Gay WA Jr. Options for repair of a bicuspid aortic valve and ascending aortic aneurysm. *Ann Thorac Surg* 2000;69:1333-1337.

Absi TS, Sundt TM, Tung WS, Moon M, Lee JK, Damiano RR, Thompson RW. Altered patterns of gene expression distinguishing ascending aortic aneurysms from abdominal aortic aneurysms: complementary DNA expression profiling in the molecular characterization of aortic disease. *J Thorac Cardiovasc Surg* 2003;126:344-357.

Okamoto RJ, Xu HD, Kouchoukos NT, Moon MR, Sundt TM. The influence of mechanical properties on wall stress and distensibility of the dilated ascending aorta. *J Thorac Cardiovasc Surg* 2003;126:842-850.

Majumdar R, Yagubyan M, Sarkar G, Bolander ME, Sundt TM. Bicuspid aortic valve and ascending aortic aneurysm are not associated with germline or somatic homeobox NKX2-5 gene polymorphism in 19 patients. *J Thorac Cardiovasc Surg* 2006;131:1301-1305.

## JOSEPH A. DEARANI, MD

Dr Dearani's main areas of investigation include congenital heart disease, with a specific interest in late-outcome data for large numbers of patients with congenital heart disease. Drawing on a large Mayo Clinic surgical database and clinical experience, he is investigating the late results of patients with congenital heart disease who initially have surgery during childhood and live into their adult years. Many of these patients require repeat operations during adult life. Risks and benefits of reoperation and long-term survival with quality-of-life issues are the focus of these studies.

In addition, he has a special interest in the pathology of congenital heart disease, with emphasis on surgical-pathological correlation. The largest collection of cardiovascular pathology specimens in the world resides in Minnesota at both the Jesse E. Edwards Registry of Cardiovascular Disease in St Paul and at Mayo Clinic in Rochester. Drawing on this large database and collaboration, he is currently writing a textbook on the pathology of congenital heart disease.



### SELECTED PUBLICATIONS

Boston US, Dearani JA, O'Leary PW, Driscoll DJ, Danielson GK. Tricuspid valve repair for Ebstein's anomaly in young children: a 30-year experience. *Ann Thorac Surg* 2006;81: 690-695.

Dearani JA, O'Leary PW, Danielson GK. Surgical treatment of Ebstein's malformation: state of the art in 2006. *Cardiol Young* 2006;16 (Suppl 3):12-20.

Suri RM, Dearani JA, Schaff HV, Danielson GK, Puga FJ. Long-term results of the Konno procedure for complex left ventricular outflow tract obstruction. *J Thorac Cardiovasc Surg* 2006;132:1064-1071.

Bartz PJ, Dearani JA, Puga FJ, Danielson GKJ, Cabalka AK, Driscoll DJ, Earing MG, Hagler DJ, O'Leary PW, Warnes CA, Connolly HM, Ammass NM, Grogan M, Hodge DO, Cetta F. Early and late results of the modified Fontan operation for heterotaxy syndrome: 30 years of experience with 142 patients. *J Am Coll Cardiol* 2006;48:2301-2305.

Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM, Schaff HV. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. *Ann Thorac Surg* 2006;82:494-501.

Suri RM, Schaff HV, Dearani JA, Sundt TM, Daly RC, Mullany CJ, Enriquez-Sarano M, Orszulak TA. Survival advantage and improved durability of mitral repair for leaflet prolapse subsets in the current era. *Ann Thorac Surg* 2006;82:819-827.

## RICHARD C. DALY, MD

Dr Daly is the principal investigator at Mayo Clinic Rochester for several clinical trials, including

- the STICH trial (Surgical Treatment of Ischemic Heart Failure), a multicenter, prospective, randomized trial comparing coronary artery bypass grafting to medical therapy for patients with ischemic cardiomyopathy. The trial will also evaluate the effectiveness of surgical ventricular remodeling for ischemic cardiomyopathy.
- a multicenter, prospective, randomized trial comparing the HeartMate II and HeartMate XVE left ventricular assist devices as permanent destination therapy.
- a multicenter, prospective trial evaluating the Jarvik 2000 left ventricular assist device as a bridge to transplantation.

Dr Daly has been involved with the development of a new surgical instrument that allows mitral valve repair by placing artificial chordae tendineae into the mitral leaflets in an off-pump manner that may lead to a minimally invasive approach to repair mitral insufficiency.

He is also involved with clinical investigations into tricuspid insufficiency after heart transplantation, combined heart-and-liver or heart-and-kidney transplantation, heart transplantation with HLA mismatch and with HLA antigen-antibody mismatch, and ischemic mitral insufficiency.



### SELECTED PUBLICATIONS

Daly RC, Dearani JA, McGregor CG, Mullany CJ, Orszulak TA, Puga FJ, Schaff HV, Sundt TM 3rd, Zehr KJ. Fifty years of open heart surgery at the Mayo Clinic. *Mayo Clin Proc* 2005;80:636-640.

Suri RM, Daly RC, Dearani JA, McGregor CGA. Successful use of Thoratec biventricular support in a small child awaiting cardiac transplantation. *Ann Thorac Surg* 2005;80:1920-1922.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. *J Heart Lung Transplant* 2005;24:2129-2136.

Ahmari SAL, Bunch TJ, Chandra A, Chandra V, Ujino K, Daly RC, Kushwaha SS, Edwards BS, Maalouf YF, Seward J, McGregor CG, Chandrasekaran K. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter. *J Heart Lung Transplant* 2006; 25:53-60.

Hillis GS, Zehr KJ, Williams AW, Schaff HV, Orszulak TA, Daly RC, Mullany CJ, Rodeheffer RJ, Oh JK. Outcome of patients with low ejection fraction undergoing coronary artery bypass grafting: renal function and mortality after 3.8 years. *Circulation* 2006;114(Suppl 1):I414-I419.



## RAKESH M. SURI, MD

Myxomatous mitral valve disease has an occult onset and insidiously progresses in young healthy individuals, with clinical manifestations such as stroke, atrial fibrillation, endocarditis, and mitral regurgitation developing later in life. Because mitral regurgitation has a nonspecific clinical presentation, the potential to lead to complications including progressive cardiac dilation with irreversible impairment of ventricular function is significant. The importance of early diagnosis and effective treatment for this condition is central to restoring normal long-term life expectancy in affected individuals.

Dr Suri and his colleagues have demonstrated that delaying mitral valve repair until the development of symptoms, deterioration in left heart function, or increase in left ventricular end-systolic dimension results in increased morbidity. His data suggest that mitral repair should be considered early in individuals with severe mitral valve regurgitation due to leaflet prolapse to optimize the chance for long-term recovery of ventricular function and survival. They have also shown that survival after valve repair is superior to that seen after prosthetic valve replacement with long-term durability that is equivalent to mechanical valve substitutes.

The use of high definition imaging systems and robotic technology have been associated with decreased length of postoperative ventilatory support, shorter hospital stay, decreased postoperative functional limitation, and quicker return to normal activities. Dr Suri and his team are exploring new ways to perform traditional cardiac surgery through smaller and better tolerated incisions while ensuring that patients benefit from the same durable results offered by traditional

“open” chest approaches. They are also working to develop new methods to perform robotic assisted coronary bypass surgery and aortic valve replacement in a robotic laboratory.

Dr Suri and colleagues have identified protein abnormalities in myxomatous mitral leaflet tissue. These altered proteins may become targets of natural immunity causing the body to attack the otherwise normal mitral valve and leading to weakening or rupture of chordae, leaflet prolapse, and regurgitation. Better understanding of this process may lead to the development of new ways to prevent the onset and slow the progression of myxomatous valve disease.

### SELECTED PUBLICATIONS

Suri RM, Schaff HV, Dearani JA, Sundt TM 3rd, Daly RC, Mullany CJ, Enriquez-Sarano M, Orszulak TA. Recurrent mitral regurgitation after repair: should the mitral valve be re-repaired? *J Thorac Cardiovasc Surg* 2006;132:1390-1397.

Suri RM, Schaff HV, Dearani JA, Sundt TM 3rd, Daly RC, Mullany CJ, Enriquez-Sarano M, Orszulak TA. Survival advantage and improved durability of mitral repair for leaflet prolapse subsets in the current era. *Ann Thorac Surg* 2006;82:819-827.

Suri RM, Orszulak TA. Triangular resection for repair of mitral regurgitation due to degenerative disease. *Oper Tech Thorac Cardiovasc Surg* 2005;10:194-199.

## SOON J. PARK, MD

Congestive heart failure affects millions of people in the United States, and about 100,000 have such advanced heart failure that heart replacement is the only viable therapeutic alternative. Research has resulted in the development of clinically acceptable ventricular assist devices (VADs) suitable for long-term use. This “destination therapy” is rapidly gaining acceptance as treatment for qualified patients with refractory symptoms. Dr Park is actively involved in clinical trials evaluating indications and function of new VADs, as well as those involving long-term follow-up. A new generation of axial flow pumps (HeartMate II) and centrifugal flow pumps (VentrAssist) are currently being evaluated. Other newer-generation pumps will soon be in clinical trials. The effects of these nonpulsatile pumps on other organ systems such as the brain, kidney, liver, and blood cells are of strong clinical interest. Clinical care pathways of appropriate transition from medical therapy to implanted cardioverter defibrillator/biventricular pacing to VAD as a destination therapy are being developed. Dr Park is also pursuing parallel research at a tissue level in heart failure, including myocardial recovery and reversed remodeling after stem cell injections. He is leading a multidisciplinary team of surgeons, cardiologists, and basic scientists who are developing a comprehensive, integrated approach to bench and clinical heart failure research, diagnosis, and treatment.



### SELECTED PUBLICATIONS

Park SJ, Nguyen DQ, Bank AJ, Ormaza S, Bolman RM 3rd. Left ventricular assist device bridge therapy for acute myocardial infarction. *Ann Thorac Surg* 2000;69:1146-1151.

Rose AG, Park SJ, Bank AJ, Miller LW. Partial aortic valve fusion induced by left ventricular assist device. *Ann Thorac Surg* 2000;70:1270-1274.

Park SJ, Liao KK, Seguro R, Madhu KP, Miller LW. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park's stitch). *J Thorac Cardiovasc Surg* 2004;127:264-266.

Dowling RD, Park SJ, Pagani FD, Tector AJ, Naka Y, Icenogle TB, Poirier VL, Frazier OH. HeartMate VE LVAS design enhancements and its impact on device reliability. *Eur J Cardiothorac Surg* 2004;25:958-963.

Park SJ, Tector A, Piccioni W, Raines E, Gelijns A, Moskowitz A, Rose E, Holman W, Furukawa S, Frazier OH, Dembitsky W. Left ventricular assist devices as destination therapy: a new look at survival. *J Thorac Cardiovasc Surg* 2005;129:9-17.

## IFTIKHAR J. KULLO, MD

Dr Kullo's work is focused on validating biomarkers of cardiovascular risk including genetic and proteomic markers as well as noninvasive measures of arterial function. Three main projects are ongoing:

- Genetic bases of atherosclerotic vascular disease (grant from the National Heart, Lung, and Blood Institute). The goal of this project is to identify the genetic determinants of peripheral arterial disease using both linkage and association approaches.
- Proteomic markers of arteriosclerosis (grant from the National Heart, Lung, and Blood Institute). The goal of this project is to study the association of novel protein markers in etiologic pathways of vascular disease with quantitative phenotypes of arteriosclerotic vascular disease (coronary artery calcium, cerebral leukoaraiosis, albuminuria, and ankle brachial index).
- Physiologic markers of arterial function. The goal of this project is to evaluate the association of measures of arterial function with vascular disease phenotypes in 2 large community-based cohorts.

The motivating hypothesis of all this research is that functional arterial measures (endothelial function and arterial stiffness) provide integrated assessments of the effects of diverse vascular risk factors and are associated with structural changes of arteriosclerosis. Dr Kullo is investigating whether measures of arterial wall function improve the prediction of quantitative measures of arteriosclerosis beyond what is possible with current algorithms for risk assessment (eg, the Framingham Risk Score).



### SELECTED PUBLICATIONS

Kullo IJ, Khaleghi M, Hensrud DD. Markers of inflammation are inversely associated with VO<sub>2</sub> max in asymptomatic men. *J Appl Physiol* 2007;102:1374-1379.

Ding K, Kullo IJ. Molecular population genetics of PCSK9: a signature of recent positive selection. *Pharmacogenomics* 2008;18:169-179.

Wang HJ, Ding K, Zhang Y, Jin L, Kullo IJ, He F. Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. *Pharmacogenomics* 2007;17:667-678.

Kullo IJ, Ding K. The genetic basis of coronary heart disease. *Nat Clin Pract Cardiovasc Med* 2007;4:558-569.

Klos KL, Kullo IJ. Genetic determinants of HDL: monogenic disorders and contributions to variation. *Curr Opin Cardiol* 2007;22:344-351.



## VÉRONIQUE L. ROGER, MD, MPH

Dr Roger is chair of the Department of Health Sciences Research at Mayo Clinic. Her research focuses on myocardial infarction and heart failure using a community-based approach. This ongoing work integrates classical tools of large-scale, population-based epidemiology with the measurement of novel biomarkers and imaging to further understanding of the burden of heart disease. Her research is supported by several research grants from the National Heart, Lung, and Blood Institute as well as an Established Investigator Award from the American Heart Association.



### SELECTED PUBLICATIONS

Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian BS, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. *JAMA* 2004;292:344-350.

Bursi F, Enriquez-Sarano M, Nkomo VT, Jacobsen SJ, Weston SA, Meverden RA, Roger VL. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. *Circulation* 2005;111:295-301.


Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, Roger VL. Secular trends in death from cardiovascular diseases: a 25-year community study. *Circulation* 2006;113:2285-2292.

Roger VL, Killian J, Weston SA, Jaffe A, Kors J, Santrach P, Jacobsen SJ, Weston SA, Meverden RA. The new criteria for the diagnosis of myocardial infarction: prospective evaluation in the community. *Circulation* 2006;114:790-797.

Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. *JAMA* 2006;296:2209-2216.

## ALLAN S. JAFFE, MD

Dr Jaffe has spent his career investigating markers of myocardial injury, hemodynamic compromise, and hemostasis in patients with acute ischemic heart disease. He has a joint appointment in the Division of Cardiovascular Diseases and in the Department of Laboratory Medicine and Pathology where he is the medical director of cardiovascular laboratory medicine. His research involves assessment of clinical utility of markers such as troponin, creatine kinase MB, natriuretic peptides, and C-reactive protein as well as novel markers of cardiovascular abnormalities in patients with acute disease, usually ischemic heart disease and/or congestive heart failure. His research is extensively funded, and he has access through his clinical activities and that of collaborators to substantial numbers of patients.



### SELECTED PUBLICATIONS

Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AHB, Tate J, Pagani F, Christenson RH, Jaffe AS. Quality specifications for B-type natriuretic peptide assays. *Clin Chem* 2005;51:486-493.

Apple FS, Wu AHB, Johannes M, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clin Chem* 2005;51:810-824.

Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. *J Am Coll Cardiol* 2006;48:1-11.

Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. *Circulation* 2007;116:249-257.

Kavsak PA, MacRae AR, Palomaki GE, Newman AM, Ko DT, Lustig V, Tu JV, Jaffe AS. Health outcomes categorized by current and previous definitions of acute myocardial infarction in an unselected cohort of troponin naïve emergency department patients. *Clin Chem* 2006;52:2028-2035.

## HENRY H. TING, MD, MBA

Dr Ting's clinical research is focused on quality improvement, health services, innovative models for health care delivery, and outcomes research. His research interests have included ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, drug-eluting stents, vascular closure devices, and percutaneous coronary intervention without on-site surgery involving large clinical registries, including the National Registry of Myocardial Infarction, American College of Cardiology National Cardiovascular Data Registry, and ACC-ACTION Registry. His work in quality improvement has used methods including Lean, Six Sigma, value network analysis, and Baldrige performance excellence criteria.



### SELECTED PUBLICATIONS

Ting HH, Raveendran G, Lennon RJ, Long KH, Singh M, Wood DL, Gersh BJ, Rihal CS, Holmes DR. A total of 1,007 percutaneous coronary interventions without on-site cardiac surgery: acute and long-term outcomes. *J Am Coll Cardiol* 2006;47:1713-1721.

Ting HH, Yang EY, Rihal CS. Reperfusion strategies for ST-segment elevation myocardial infarction. *Ann Intern Med* 2006;145:610-617.

Doyle BJ, Konz BA, Lennon RJ, Bresnahan JF, Rihal CS, Ting HH. Early ambulation one hour after diagnostic cardiac catheterization: a prospective study of 1009 procedures. *Mayo Clin Proc* 2006;81:1537-1540.

Ting HH, Long KH, Galvin RS, Petersen LA, Krumholz HM. Do economic incentives improve healthcare quality? implications for pay for performance. American College of Cardiology Cardiosource Web site. Available at <http://www.cardiosource.com/expertopinions/hottopics/article.asp?paperID=264>. Accessed May 30, 2007.

Ting HH, Rihal CS, Gersh BJ, Haro LH, Bjerke CM, Lennon RJ, Lim CC, Bresnahan JF, Jaffe AS, Holmes DR, Bell MR. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. *Circulation* 2007;116:729-736.



## GERALD T. GAU, MD

The focus of his research is preventive cardiology, particularly in the field of lipidology, and most recently the use of nuclear magnetic resonance technology to look at lipid particles in patients with complex lipid conditions as well as novel coronary disease risk factors.

With the National Institutes of Health, Dr Gau is investigating the use of chelation therapy in high-risk coronary patients enrolled in a continuing trial to look at chelation's possible value. In the Cardiovascular Health Clinic, prevention of both primary and secondary coronary disease is his main research emphasis.

### SELECTED PUBLICATIONS

Lopez-Jimenez F, Sierra Johnson J, Somers VK, Gau GT. Dyslipidemia and classical factors for atherosclerosis. In: Murphy JG, Lloyd MA, editors. Mayo Clinic cardiology: concise textbook. 3rd edition. Rochester, MN: Mayo Clinic Scientific Press, Informa Healthcare; 2007. pp. 715-724.

Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356:1503-1516.

Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini J, Berman DS, Gau G, Weintraub WS. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. *Am J Cardiol* 2007;99:208-212.

Gau GT, Wright RS. Pathophysiology, diagnosis, and management of dyslipidemia. *Curr Probl Cardiol* 2006;31:445-486.

## FRANCISCO LOPEZ-JIMENEZ, MD, MSc

Dr Lopez-Jimenez's research interest includes translational research assessing the effect of obesity, metabolic syndrome, and sleep apnea on cardiovascular health. His current research is testing the added value of direct measurement of body fat and the implementation of effective weight loss techniques in clinical practice. He holds several grants supporting research on bariatric surgery and cardiovascular disease mechanisms and others supporting research on dietary interventions in metabolic syndrome.



### SELECTED PUBLICATIONS

Lopez-Jimenez F, Malinski M, Gutt M, Sierra-Johnson J, Wady Aude Y, Rimawi AA, Mega PA, Thomas RJ, Allison TG, Kirby B, Hughes Borst B, Somers, VK. Recognition and management of obesity in patients after myocardial infarction. *Int J Obes Relat Metab Disord* 2005;29:137-141.

Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F. Association of body weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. *Lancet* 2006;368:666-678.

Romero-Corral A, Somers VK, Sierra-Johnson J, Jensen MD, Thomas RJ, Squires RW, Allison TG, Korinek J, Lopez-Jimenez F. Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. *Eur Heart J* 2007;28:2087-2093.

Lopez-Jimenez F, Bhatia S, Collazo-Clavell ML, Sarr MG, Somers VK. Safety and efficacy of bariatric surgery in patients with coronary artery disease. *Mayo Clin Proc* 2005;80:1157-1162.

Batsis J, Nieto-Martinez RE, Lopez-Jimenez F. Metabolic syndrome: from global epidemiology to individualized medicine. *Clin Pharmacol Ther* 2007;82:509-524.



## SHARONNE N. HAYES, MD

As director of the Women's Heart Clinic, Dr Hayes is interested in clinical research related the development, diagnosis, treatment, and prognosis of heart disease in women. She is involved in a number of clinical studies:

- Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women: The Kronos Early Estrogen Prevention Study (KEEPS)
- Noninvasive Assessment of Endothelial Function Using Endo-PAT (Endothelial-Peripheral Arterial Tonometry) in Subjects Enrolled in KEEPS (Kronos Early Estrogen Prevention Study)
- SMART Study: Stress Echocardiography in Menopausal Women at Risk for Coronary Artery Disease
- AWARE Study (Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization)

### SELECTED PUBLICATIONS

Marcuccio E, Loving N, Bennett SK, Hayes SN. A survey of attitudes and experiences of women with heart disease. *Womens Health Issues* 2003;13:23-31.

Hayes SN, Long T, Hand MM, Finnegan JR, Selker HP. Women's ischemic syndrome evaluation. Current Status and Future Research Directions: Report of the National Heart, Lung and Blood Institute Workshop: October 2-4, 2002: Section 6: Key Messages About Acute Ischemic Heart Disease in Women and Recommendations for Practice. *AHA/NHLBI Conference Proceedings. Circulation* 2004;109:59-61.

Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. *Circulation* 2005;111:499-510.

Larsen KE, Vickers KS, Sampson S, Netzel P, Hayes SN. Depression in women with heart disease: the social importance of social role performance and spirituality. *J Clin Psychol Med Settings* 2006;13:36-45.

Blauwet LA, Hayes SN, McManus D, Redberg RF, Walsh MN. Low rate of sex-specific result reporting in cardiovascular trials. *Mayo Clin Proc* 2007;82:166-170.

## THOMAS G. ALLISON, PhD, MPH

Dr Allison's research interests focus principally on exercise testing—in particular, the use of cardiopulmonary exercise testing for risk stratification and selection of patients with complex cardiac disease for surgical intervention. The Cardiovascular Health Clinic has a large database of exercise testing results that Dr Allison is evaluating. Mortality and other data are being analyzed to better understand predictors of clinical outcomes.

He is also interested in coronary risk factor management, especially the practical aspects of managing risk factors in clinical practice.



### SELECTED PUBLICATIONS

Allison TG, Farkouh ME, Smars PA, Evans RW, Squires RW, Gabriel SE, Kopecky SL, MD, Ibbons RJ, Reeder GS. Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (a Chest Pain Evaluation in the Emergency Room [CHEER] substudy). *Am J Cardiol* 2000;86:133-138.

Kim C, Gau GT, Allison TG. Relation of high lipoprotein(a) to other traditional atherosclerotic risk factors in patients with coronary heart disease. *Am J Cardiol* 2003;91:1360-1363.

Leung T-C, Ballman KV, Allison TG, Wagner JA, Olson LJ, Frantz RP, Edwards BS, Dearani JA, Daly RC, McGregor CGA, Rodeheffer RJ. Clinical predictors of exercise capacity 1 year after cardiac transplantation. *J Heart Lung Transplant* 2003;22:16-27.

Sierra Johnson J, Wright RS, Lopez-Jimenez F, Allison TG. Relation of body mass index to fatal and non-fatal cardiovascular events after cardiac rehabilitation. *Am J Cardiol* 2005;96:211-214.

Messika-Zeitoun D, Johnson BD, Nkomo V, Avierinos JF, Allison TG, Scott C, Tajik AJ, Enriquez-Sarano M. Cardiopulmonary exercise testing determination of functional capacity in mitral regurgitation: physiologic and outcome implications. *J Am Coll Cardiol* 2006;47:2521-2527.

## RANDAL J. THOMAS, MD, MS

Dr Thomas's research work is focused on finding ways to reduce the so-called prevention gap—the gap in the use of preventive strategies of known efficacy in clinical practice. These efforts are centered on 2 main areas of study:

- Cardiovascular risk assessment, using primary and secondary database analysis from the Mayo Clinic Cardiovascular Health Clinic database, as well as other Mayo Clinic and national databases.
- Cardiovascular risk reduction, exploring ways to better define and apply appropriate preventive therapies in the clinical and community settings.

Current research protocols include a project to assess a novel risk assessment tool for vascular health (arterial augmentation index) and 2 projects aimed at identifying and reducing barriers to secondary prevention strategies for patients with cardiovascular disease.



### SELECTED PUBLICATIONS

Thomas RJ. Can familial combined hyperlipidemia diagnostic criteria be improved by the use of nomogram? *Nat Clin Pract Cardiovasc Med* 2004;1:78-79.

Bogar MD, Basford JR, Thomas RJ. Rate and adequacy of cholesterol screening in patients admitted to a large rehabilitation unit after stroke. *Arch Phys Med Rehabil* 2005;86:69-72.

Witt BJ, Thomas RJ, Roger VL. Cardiac rehabilitation after myocardial infarction: a review to understand barriers to participation and potential solutions. *Eura Medicophys* 2005;41:27-34.

Thomas RJ, Witt BJ, Lopez-Jimenez F, King ML, Squires RW. Quality indicators in cardiovascular care: the case for cardiac rehabilitation. *J Cardiopulm Rehabil* 2005;25:249-256.

Thomas RJ, King M, Lui K, Oldridge N, Pina IL, Spertus J; American Association of Cardiovascular and Pulmonary Rehabilitation/ American College of Cardiology/ American Heart Association Cardiac Rehabilitation/ Secondary Prevention Performance Measures Writing Committee. AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services. *Circulation* 2007;116:1611-1642.



## SHARON L. MULVAGH, MD

Dr Mulvagh's research interests include risk assessment for coronary disease in women. Current active protocols include

- Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women: The Kronos Early Estrogen Prevention Study (KEEPS)
- Noninvasive Assessment of Endothelial Function Using Endo-PAT (Endothelial-Peripheral Arterial Tonometry) in Subjects Enrolled in KEEPS (Kronos Early Estrogen Prevention Study)
- SMART: Stress Echocardiography in Menopausal Women at Risk for Coronary Artery Disease



### SELECTED PUBLICATIONS

Miller VM, Mulvagh SL. Sex steroids and endothelial function: translating basic science to clinical practice. *Trends Pharmacol Sci* 2007;28:263-270.


Hsia JA, DeVita JA, Mulvagh SL, Lewis J, Canossa Terris M, Han G, Prescott ME. Influence of blood pressure vs overweight/obesity on biomarkers of vascular health in postmenopausal women. *J Am Coll Cardiol* 2006;47:300A.

Moir WS, Ness SA, Pellikka PA, Abdelmoneim S, Bott-Kitslaar D, Hayes SN, Mulvagh SL. Does the Framingham risk score predict coronary artery disease in early menopausal women referred for stress echocardiography? a contrast echocardiography, cardiac CT and serum biomarker study. *J Am Soc Echocardiogr* 2006;19:644.

## HON-CHI LEE, MD, PHD

The major focus of Dr Lee's research is to understand the regulation of ion channels in the cardiovascular system. He uses patch clamp and microelectrode techniques to measure action potentials and ionic currents in cardiovascular tissues and cells. He also uses biochemical and molecular approaches to examine ion channel expression, cellular trafficking, membrane targeting, and the effect of mutagenesis on structure-function relationships. Specific active projects include

- Studies on the role of lipid metabolites in the regulation of potassium channels in heart and blood vessels.
- The role of endothelium-derived hyperpolarizing factors on vascular ion channel activities and on the regulation of vasoreactivity.
- New motifs of ion channel regulation, including the role of membrane microdomain targeting.
- Abnormal ion channel regulation in disease states such as diabetes and the role of reactive oxygen species on ion channel function.
- Novel approaches in the treatment of heart rhythm problems such as cellular therapy of cardiac arrhythmias.
- Use of proteomics approaches on cardiovascular diseases.



### SELECTED PUBLICATIONS

Lu T, Wang X-L, He T, Zhou W, Kaduce TL, Spector AA, Lee H. Reduced arachidonic acid-mediated activation of BK channels in coronary arterial smooth muscle cells in Zucker diabetic fatty rats due to impaired cyclooxygenase activities. *Diabetes* 2005;54:2155-2163.

Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller V, Wang X-L, Lee H, Caplice NM, Packer DL. Focal modification of the canine AV node with targeted perinodal injections of autologous fibroblasts, TGF beta 1, and a combination of both. *Circulation* 2006;113:2485-2494.

Lu T, Ye D, Wang X-L, Seubert JM, Graves JP, Bradbury JA, Zeldin DC, Lee H. Activation of KATP channels by endogenous cytochrome P450 epoxygenase metabolites of arachidonic acid: cardiac and vascular KATP channels are activated by epoxyeicosatrienoic acids through different mechanisms. *J Physiol* 2006;575:627-644.

Lu T, He T, Katusic ZS, Lee H. Molecular mechanisms mediating inhibition of human large conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channels by high glucose. *Circ Res* 2006;99:607-616.

Wang X-L, Fu A, Raghavakaimal S, and Lee H. Proteomic analysis of vascular endothelial cells in response to laminar shear stress. *Proteomics* 2007;7:588-596.

## MICHAEL J. ACKERMAN, MD, PhD

Dr Ackerman's research program is endowed as the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory and is dedicated to the discovery of novel disease-causing genes and the elucidation of genotype-phenotype relationships for

- the most common causes of autopsy-negative sudden death, namely, the cardiac channelopathies that include long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT)
- sudden infant death syndrome (SIDS)
- the most common cause of autopsy-positive sudden death in young people, especially athletes, namely, hypertrophic cardiomyopathy (HCM)

In addition, as director of the Long QT Syndrome Clinic, Dr Ackerman has active clinical translational research efforts devoted to identifying individuals at greatest risk for sudden death. These projects include autonomic nervous system studies and overnight sleep studies. During the past 12 months, his laboratory has published articles describing 6 novel disease-susceptibility genes for LQTS, SIDS, and HCM. In May 2007, Dr Ackerman received the 25th Young Investigator Award from the Society for Pediatric Research. In July 2007, his National Institutes of Health grant, "Cardiac Channel Mutations in Sudden Infant Death Syndrome," was renewed.



### SELECTED PUBLICATIONS

Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. *J Am Coll Cardiol* 2007;9:240-246.

Cronk LB, Ye B, Kaku T, Tester DJ, Vatta M, Makielski JC, Ackerman MJ. A novel mechanism for sudden infant death syndrome (SIDS): persistent late sodium current secondary to mutations in caveolin-3. *Heart Rhythm* 2007;4:161-166.

Taggart NW, Haglund CM, Tester DJ, Ackerman MJ. Diagnostic miscues in congenital long QT syndrome. *Circulation* 2007;115:2613-2620.

Landstrom A, Batalden KB, Weisleder N, Bos JM, Tester DJ, Ommen SR, Wehrens XHT, Claycomb WC, Ko J, Hwang M, Pan Z, Ma J, Ackerman MJ. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. *J Molec Cell Cardiol* 2007;42:1026-1035.

Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B, Valdivia C, Ueda K, Canizales-Quinteros A, Tusié-Luna M, Makielski JC, Ackerman MJ. SCN4B-encoded sodium channel  $\beta_4$  subunit in congenital long-QT syndrome. *Circulation* 2007;116:134-142.

## WIN-KUANG SHEN, MD

The focus of Dr Shen's research program has been the disease mechanisms, therapeutic intervention, and outcomes in clinical electrophysiology and cardiac devices. The disease/condition-oriented themes include syncope, orthostatic intolerance, atrial fibrillation, and sudden cardiac death. He has long been interested in these problems in the aging and elderly populations. He continues clinical investigations on the mechanisms underlying vasovagal syncope, inappropriate sinus tachycardia, atrial fibrillation, and sudden death in familial conditions. He has developed several research databases, including databases on syncope, atrial fibrillation, and cardiac devices. He has been the principal investigator of several investigator-initiated single- and multicenter clinical trials. His most recent multicenter trial, "Pacing and AV Node Ablation Compared to Drug Therapy in Symptomatic Elderly Patients With Atrial Fibrillation Clinical Trial (PACIFIC)," has been funded for the pilot phase of the study.



### SELECTED PUBLICATIONS

Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:365-373.

Shen WK, Low PA, Rea RF, Lohse CM, Hodge DO, Hammill SC. Distinct hemodynamic profiles in patients with vasovagal syncope: a heterogeneous population. *J Am Coll Cardiol* 2000;35:1470-1477.

Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. *N Engl J Med* 2001;344:1043-1051.

Shen WK, Decker WW, Smars PA, Goyal DG, Walker AE, Hodge DO, Trusty JM, Brekke KM, Jahangir A, Brady PA, Munger TM, Gersh BJ, Hammill SC, Frye RL. Syncope Evaluation in the Emergency Department Study (SEEDS): a multidisciplinary approach to syncope management. *Circulation* 2004;110:3636-3645.

Razavi M, Luria DM, Jahangir A, Hodge DO, Low PA, Shen WK. Acute blood pressure changes after the onset of atrioventricular nodal reentrant tachycardia: a time-course analysis. *J Cardiovasc Electrophysiol* 2005;16:1037-1040.

## TERESA S. TSANG, MD

Recognizing the continued growth of the population of older persons in the United States, many of whom suffer from age-related cardiovascular conditions, Dr Tsang's research team is dedicated to research endeavors that will enhance understanding of cardiovascular physiologic aging. Her work focuses on testing novel noninvasive techniques for the prediction and prevention of age-related cardiovascular and cerebrovascular outcomes, including atrial fibrillation, stroke, heart failure, ischemic heart disease, and cognitive dysfunction. Her team has been particularly interested in the epidemiology of atrial fibrillation and echocardiographic prediction and prevention of this and other age-related cardiovascular conditions.

Dr Tsang has conducted pilot clinical trials for modification of some of the factors leading to atrial fibrillation, such as diastolic dysfunction and left atrial remodeling. In collaboration with colleagues in neurology, she is also actively conducting studies looking at the relationship between cardiovascular risk factors and cognitive function as well as stroke.



### SELECTED PUBLICATIONS

Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TSM. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006;114:119-125.

Tsang TSM, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. *J Am Coll Cardiol* 2002;40:1636-1644.

Tsang TSM, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, Seward JB. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. *J Am Coll Cardiol* 2003;42:1199-1205.

Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TSM. Left atrial size: physiologic determinants and clinical application. *J Am Coll Cardiol* 2006;47:2357-2363.

Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, Casaclang-Verzosa G, Abhayaratna WP, Seward JB, Iwasaka T, Tsang TSM. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. *Eur Heart J* 2007;28:1962-1967.


## ANDRE TERZIC, MD, PhD

Dr Terzic is director of the Mayo Clinic Marriott Heart Disease Research Program. His specific areas of interest include

- Cardioprotective and cardioregenerative medicine
- Stem cells and developmental cardiac biology
- Genetics of cardiac disease and stress tolerance in health and disease
- Bioenergetic signaling, nucleocytoplasmic communication, and ion channel biology
- Ischemic heart disease, heart failure, cardiomyopathy, and atrial fibrillation

The priority of this multidisciplinary research program is to decipher molecular pathways of stress tolerance and to identify the genetic basis of maladaptation in human disease. This ongoing work has evolved along the principles of metabolomic matrix networks and biocatalysis applied to the pathogenetics of cardiac disease, such as heart failure.

Dr Terzic's integrative research is at the interface of biophysics, biochemistry, physiology, and medicine and has led to the discovery of the vital role for membrane metabolic sensors in decoding signs of energy distress. The promise that lies ahead is in the translation of the fundamental principles of stress adaptation, established for the heart and tested in discrete patient cohorts, into broader diagnostic and therapeutic screens applied to diverse disease entities and the population at large. In particular, early genetic detection of disease susceptibility for each individual and treatment by targeted stem cell-based repair deficits provide opportunities for the further advancement of cardiovascular medicine in the decade ahead.



### SELECTED PUBLICATIONS

Yamada S, Kane GC, Behfar A, Liu X-K, Dyer RB, Faustino RS, Miki T, Seino S, Terzic A. Protection conferred by myocardial ATP-sensitive K<sup>+</sup> channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. *J Physiol* 2006;577:1053-1065.

Olson TM, Alekseev AE, Moreau C, Liu X-K, Zingman LV, Miki T, Seino S, Asirvatham SJ, Jahangir A, Terzic A. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. *Nat Clin Pract Cardiovasc Med* 2007;4:110-116.

Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM, Yamada S, Puceat M, Niederländer N, Alekseev AE, Zingman LV, Terzic A. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. *J Exp Med* 2007;204:405-420.

Chung S, Dzeja PP, Faustino RS, Perez-Terzic C, Behfar A, Terzic A. Switch in energy metabolism with mitochondria network maturation supports cardiac differentiation of stem cells. *Nat Clin Pract Cardiovasc Med* 2007;4:S60-S67.

Perez-Terzic C, Faustino RS, Boorsma BJ, Arrell DK, Niederlander NJ, Behfar A, Terzic A. Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport machinery. *Nat Clin Pract Cardiovasc Med* 2007;4:S68-S76.

## TIMOTHY M. OLSON, MD

The objective of Dr Olson's research program is to identify mutations in genes that cause or confer susceptibility to mechanical dysfunction and electrical instability in the heart. His molecular genetic studies focus on 2 heritable disorders in humans: idiopathic dilated cardiomyopathy and atrial fibrillation. Experimental strategies include genetic linkage analysis to map the genomic location of novel disease genes in familial cases and hypothesis-based mutational analyses of candidate genes. These investigations utilize technologically advanced, automated systems for high-throughput DNA analysis and capitalize on genomic information derived from the Human Genome Project. The long-term objective of his research is to gain new insights into molecular mechanisms for congestive heart failure and arrhythmias and apply this knowledge to improve diagnosis, treatment, and prevention of heart disease.



### SELECTED PUBLICATIONS

Bienengraeber M, Olson TM, Selivanov VA, Kathmann EC, O'Coilain F, Gao F, Karger AB, Ballew JD, Hodgson DM, Zingman LV, Pang Y-P, Alekseev AE, Terzic A. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. *Nat Genet* 2004;36:382-387.

Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, Rodeheffer RJ, Anderson JL. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. *JAMA* 2005;293:447-454.

Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, Terzic A. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. *Hum Mol Genet* 2006;15:2185-2191.

Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ, Olson TM. A common polymorphism in SCN5A is associated with lone atrial fibrillation. *Clin Pharmacol Ther* 2007;81:35-41.

## DOUGLAS L. PACKER, MD

The focus of Dr Packer's investigative efforts in the Cardiac Electrophysiology Translational Research Laboratory is to understand the mechanisms underlying atrial fibrillation and its treatment with ablative intervention. This includes the investigation of the atrial structure/activity relationships in the left atrium and pulmonary veins. His group is developing 4- and 5-dimensional imaging techniques to enhance cardiac mapping approaches, which incorporate intracardiac ultrasound, computed tomography, and magnetic resonance image integration. Parallel studies for ventricular tachycardia/ventricular fibrillation ablation use this technology to create ablation paradigms for unstable ventricular tachycardia. He also seeks to discover cell therapies for modulating conduction during atrial fibrillation in the setting of ventricular dysfunction. With this, he hopes to design better interventional therapies for atrial arrhythmias and counter the conduction abnormalities present in cardiomyopathies. This work forms the translational basis for innovative therapies in the Clinical EP Laboratory, where Dr Packer is conducting parallel investigations. These studies are funded in part by the National Institutes of Health and the Mayo Clinic clinical investigator program.



### SELECTED PUBLICATIONS

Natale A, Raviele A, Arentz T, Calkins H, Chen SA, Haissaguerre M, Hindricks G, Ho Y, Kuck KH, Marchlinski F, Napolitano C, Packer D, Pappone C, Prystowsky EN, Schilling R, Shah D, Themistoclakis S, Verma A, for the Venice Chart members. Venice Chart international consensus document on atrial fibrillation ablation. *J Cardiovasc Electrophysiol* 2007;18:560-580.

Cravens GT, Packer DL, Johnson ME. Incidence of propofol infusion syndrome during non-invasive radiofrequency ablation for atrial flutter or fibrillation. *Anesthesiology* 2007;106:1134-1138.

Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for personnel, policy, procedures and follow-up: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation; developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS); endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. *Heart Rhythm* 2007; 4:816-861.

Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller DV, Horne BD, Wang XL, Lee HC, Caplice NM, Packer DL. Impact of transforming growth factor-beta1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. *Circulation* 2006;113:2485-2494.



## NASER M. AMMASH, MD

Dr Ammash's research focus has been adult congenital heart disease, sleep apnea, and atrial fibrillation. His research projects include pacing and cardioversion in adults with congenital heart disease. He is also actively recruiting patients with cyanotic congenital heart disease for sleep apnea evaluation to further understand the specific pathophysiologic pathways linking sleep disorders in these patients who are believed to be predisposed to sleep-disordered breathing and autonomic cardiovascular abnormalities.

Dr Ammash has 2 additional active projects focusing on atrial fibrillation. He and his colleagues have already demonstrated the association between atrial fibrillation and sleep apnea. Their next aim is to show that, in these patients, treatment of sleep apnea with continuous positive airway pressure reduces the rate of recurrence of atrial fibrillation after cardioversion. A randomized, controlled clinical trial is under way through the cardioversion unit that he directs. Most recently, he also started analyzing the possible link between von Willebrand factor, its cleavage enzyme ADAMTS-13, and the development of low flow state and atrial thrombi in patients with atrial fibrillation undergoing transesophageal echocardiographically guided cardioversion.



### SELECTED PUBLICATIONS

Ammash N, Warnes CA. Unoperated single ventricle: survival into adulthood. *Am J Cardiol* 1996;77:542-544.

Ammash N, Seward JB, Warnes CA, Connolly HM, O'Leary PW, Danielson GK. Partial anomalous pulmonary venous connection: TEE diagnosis. *J Am Coll Cardiol* 1997;29:1351-1358.

Ammash N, Connolly HM, Abel M, Warnes CA. Noncardiac surgery in Eisenmenger syndrome. *J Am Coll Cardiol* 1999;33:222-227.

Ammash N, Warnes CA. Ventricular septal defects in adults: a review. *Ann Intern Med* 2001;135:812-824.

Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, Malouf JF, Ammash N, Friedman PA, Somers VK. Association of atrial fibrillation and obstructive sleep apnea. *Circulation* 2004;27;110:364-367.

Kanagala R, Murali NS, Friedman PA, Ammash N, Gersh BJ, Ballman KV, Shamsuzzaman ASM, Somers VK. Obstructive sleep apnea and the recurrence of atrial fibrillation. *Circulation* 2003; 107:2589-2594.

Stoddard MF, Dawkins P, Prince C, Ammash N. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and recent embolic event: a transesophageal echocardiographic study. *J Am Coll Cardiol* 1995;25:452-459.

## ROBERT D. SIMARI, MD

The focus of research in Dr Simari's laboratory is to define the biologic response to vascular injury and to utilize these mechanisms to develop novel biologic therapeutics. The laboratory has multiple National Institutes of Health-funded projects to support both major areas. In 1 protocol, for example, laboratory members have established unique murine models to study the role of the tissue factor pathway on vascular form and function. These models include tissue-specific overexpression and tissue-specific deletion of tissue factor pathway inhibitor. These mice allow Dr Simari to define how the tissue factor pathway is regulated in development and disease with a specific interest in thrombosis. This study was funded by the National Heart, Lung, and Blood Institute (NHLBI).

Dr Simari is interested in the role of circulating progenitor cells in the response to vascular injury. He has established a model by which he delivers autologously derived endothelial progenitors following vascular injury. Sources of cells currently being tested include blood, bone marrow, and fat. This study is also funded by NHLBI.

He is applying knowledge of circulation progenitors to the field of left ventricular (LV) dysfunction in collaboration with Drs John Burnett, Horng Chen, and Margaret Redfield as part of a program project grant on natriuretic peptides. They have demonstrated regulation of circulating progenitors in the setting of LV dysfunction and are developing means to deliver cells to reverse the process. They have also discovered a novel form of BNP, the result of alternative splicing which has unique biologic effects.

Dr Simari was recently named the national chair of the Cardiovascular Cell Therapy Research Network funded by the NHLBI, which provides an opportunity to participate in a unique multicenter network to perform cell therapy studies for LV dysfunction.



### SELECTED PUBLICATIONS

Gulati R, Jevremovic D, Peterson TE, Witt TA, Kleppe LS, Mueske CS, Lerman A, Vile RG, Simari RD. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. *Circulation* 2003;108:1520-1526.

Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, Simari RD. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. *Circ Res* 2003;93:1023-1025.

Smits P, Kleppe L, Witt T, Mueske C, Vile R, Simari R. Distribution of circulation-derived endothelial progenitors following systemic delivery. *Endothelium* 2007;14:1-5.

Pislaru S, Harbuzariu A, Gulati R, Witt T, Sandhu N, Simari RD, Gurpreet S. Magnetically targeted endothelial cell localization in stented vessels. *J Am Coll Cardiol* 2006;48:1839-1845.

## BIRGIT KANTOR, MD

Dr Kantor's research work is at the interface of vascular biology of atherosclerosis and cardiac imaging. She has a special interest in diabetic patients who are at increased risk of developing heart disease. Since 2000, she has been extramurally funded and is currently principal investigator on a National Institutes of Health (NIH) consortium agreement entitled "Collaterals in Aging: Enhanced by Genetic/Cell Therapy" and on a recent NIH grant entitled "In Vivo Localization of Vulnerable Plaque." In these grants, she applies dual-energy CT and microscopic CT to small and large animal models to study mechanisms of ischemia.

She is a member of 2 NIH national study sections and serves on 2 Mayo Clinic clinical research committees.



### SELECTED PUBLICATIONS


Kantor B, Jorgensen SM, Lund PE, Chmelik MS, Ritman EL. Cryostatic micro-CT imaging of arterial wall perfusion. *Scanning* 2002;24:186-190.

Kantor B, Mohlenkamp S. Imaging the myocardial microvasculature using fast computed tomography and three-dimensional microscopic computed tomography. *Cardiol Clin* 2003;21:587-605.

Zbinden S, Kantor B, Clavijo LC, Morsli H, Cortes GA, Andrews JA, Jang GJ, Burnett MS, Epstein SE. Inter-animal variability in preexisting collaterals is a major factor determining outcome in experimental angiogenesis trials. *Am J Physiol Heart Circ Physiol* 2007;292:H1891-H1897.

McCollough CH, Kantor B, Primak AN, Krauss B, Schmidt B, Flohr T, Ritman EL. Fast dual-energy, multi-slice CT can discriminate Fe and Ca. Presented at American Heart Association Scientific Sessions, 2006, session AOP.69.2, abstract No. 16734.

Gerber TC, Kantor B, Williamson EE, editors. *Computed tomography of the cardiovascular system*. London, UK: Informa Healthcare; 2007.





## FRANK V. BROZOVICH, MD, PhD

How changes in the regulation of cardiac and smooth muscle contractile proteins contribute to the human cardiovascular disease is unclear. The objective of this research program is to identify changes in protein structure and/or cell signaling that result in abnormal contractility, including hypertension and congestive heart failure. The methods in the laboratory include transgenic, molecular biological, biochemical, and biophysical experimental techniques. Using these techniques, experiments focus on identifying alterations in signaling pathways that contribute to cardiovascular disease processes and on defining the role of alternative exon splicing in the regulation of protein-protein interaction necessary for muscle contractility. The laboratory's long-term objective is to identify new targets for rational drug design for the treatment of hypertension and congestive heart failure.

### SELECTED PUBLICATIONS

El Toukhy A, Given AM, Cochard A, Brozovich FV. PHI-1 induced enhancement of myosin phosphorylation in chicken smooth muscle. *FEBS Lett* 2005;579:4271-4277.

Rhee AY, Ogut O, Brozovich FV. Non-muscle myosin, force maintenance and the tonic contractile phenotype in smooth muscle. *Pflugers Arch* 2006;452:766-774.


Chen FC, Ogut O, Rhee AY, Hoit BD, Brozovich FV. Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. *J Mol Cell Cardiol* 2006;41:488-495.

Babu GJ, Celia G, Rhee AY, Yamamura H, Takahashi K, Brozovich FV, Osol G, Periasamy M. Effects of h1-calponin ablation on the contractile properties of bladder vs. vascular smooth muscle in SM-B null mice. *J Physiol* 2006;577:1033-1042.

Given AM, Ogut O, Brozovich FV. MYPT1 mutants demonstrate the importance of aa 888-928 for the interaction with PKG1alpha. *Am J Physiol Cell Physiol* 2007;292:C432-C439.

## CHARANJIT S. RIHAL, MD, MBA

Dr Rihal's clinical and research interests are in the areas of coronary and structural heart disease. Dr Rihal has completed numerous outcomes analyses of the term results of coronary interventional procedures and has served as investigator in national studies such as Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). He currently is principal investigator of a series of studies examining markers of platelet activation in acute coronary syndromes. Dr Rihal is interested in the development of novel devices and approaches for therapeutic procedures and has performed preclinical and clinical research into novel interventional approaches to the percutaneous treatment of valvular heart disease. His interests also include the management of technologically intensive practices, and he has published on economic outcomes following interventional procedures.



### SELECTED PUBLICATIONS

Sandhu G, Doyle B, Singh R, Bell M, Bresnahan J, Mathew V, Holmes D, Lerman A, Rihal C. Frequency, etiology, treatment, and outcomes of drug-eluting stent thrombosis during one year of follow-up. *Am J Cardiol* 2007;99:465-469.

Sorajja P, Cabalka AK, Hagler DJ, Reeder GS, Chandrasekaran K, Cetta F, Rihal CS. Successful percutaneous repair of perivalvular prosthetic regurgitation. *Catheter Cardiovasc Interv* 2007;70:815-823.

Maniu CV, Patel JB, Reuter DG, Meyer DM, Edwards WD, Rihal CS, Redfield MM. Acute and chronic reduction of functional mitral regurgitation in experimental heart failure by percutaneous mitral annuloplasty. *J Am Coll Cardiol* 2004; 44:1652-1661.

Rihal CS, Kamath CC, Holmes DR, Reller MK, Anderson SS, McMurtry EK, Long KH. Economic and clinical outcomes of a physician-led continuous quality improvement intervention in the delivery of percutaneous coronary intervention. *Am J Manag Care* 2006;12:445-452.

Jacobson KM, Hall Long K, McMurtry EK, Naessens JM, Rihal CS. The economic burden of complications during percutaneous coronary intervention. *Qual Saf Health Care* 2007;16:154-159.

## DAVID R. HOLMES, JR, MD

The focus of his research has been on the interventional treatment of both coronary artery disease and structural heart disease, with the specific aim of developing new technology and then evaluating the outcomes of these new therapeutic options. Specific current projects include 1) occlusion of the left atrial appendage for stroke prevention in patients with atrial fibrillation, 2) implantable devices for early detection of ST-segment elevation myocardial infarction, and 3) development and testing of new stent designs with new polymer coatings.



### SELECTED PUBLICATIONS

Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, Popma JJ, Serruys PWJC, Kimura T, Williams DO, Windecker S, Krucoff MW. Thrombosis and drug-eluting stents: an objective appraisal. *J Am Coll Cardiol* 2007;50:109-118.

Singh M, Rihal CS, Lennon RJ, Spertus J, Rumsfeld JS, Holmes DR Jr. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. *Mayo Clin Proc* 2007;82:701-708.

Singh M, Rihal CS, Gersh BJ, Lennon RJ, Prasad A, Sorajja P, Gullerud RE, Holmes DR Jr. Twenty-five year trends in in-hospital and long-term outcome after percutaneous coronary intervention: a single-institution experience. *Circulation* 2007;115:2835-2841.

Sick PB, Schuler G, Hauptmann KE, Grube E, Yakubov S, Turi ZG, Mishkel G, Almany S, Holmes DR. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. *J Am Coll Cardiol* 2007;49:1490-1495.

Holmes DR Jr, Moses JW, Schofer J, Morice MC, Schampaert E, Leon MB. Cause of death with bare metal and sirolimus-eluting stents. *Eur Heart J* 2006;27:2815-2822.

## ABHIRAM PRASAD, MD

Dr Prasad is an interventional cardiologist with an interest in acute cardiac care. His research focuses on acute coronary syndromes. Specifically, he has ongoing research protocols investigating the role of endothelial antagonists and remote ischemic preconditioning during percutaneous coronary intervention. The studies are designed to investigate potential novel therapies to reduce myocardial injury during percutaneous coronary intervention and at the time of reperfusion therapy for myocardial infarction. In addition, he has a research interest in stress-induced cardiomyopathy, also known as apical ballooning syndrome. A Mayo Clinic registry has been established for this novel syndrome. Another avenue of investigation is outcomes research among patients undergoing percutaneous coronary intervention.



### SELECTED PUBLICATIONS

Prasad A. Apical ballooning syndrome: an important differential diagnosis of acute myocardial infarction. *Circulation* 2007;115:e56-e59.

Prasad A, Rihal C, Lennon R, Singh M, Holmes DR. Trends in outcomes following percutaneous coronary intervention for chronic total occlusions: 25 year experience from the Mayo Clinic. *J Am Coll Cardiol* 2007; 49:1611-1618.

Prasad A, Stone G, Stuckey T, Constantini C Jr, Mehran R, Garcia E, Tchong J, Cox D, Grines C, Lansky A, Gersh B. Relationship between leukocyte count, myonecrosis, myocardial perfusion and outcomes following primary angioplasty. *Am J Cardiol* 2007;99:1067-1071.

Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR, Rihal C. Isolated elevation in troponin-T following percutaneous coronary intervention is associated with higher long-term mortality. *J Am Coll Cardiol* 2006;48:1765-1770.

Elesber A, Lerman A, Bybee KA, Murphy JG, Barsness G, Singh M, Rihal CS, Prasad A. Myocardial perfusion in apical ballooning syndrome: correlate of myocardial injury. *Am Heart J* 2006;152:469.e9-469.e13.

## PATRICIA J. M. BEST, MD

The focus of Dr Best's research is to better understand the role of specific cardiovascular risk factors, including renal disease and female sex, on the development of coronary artery disease. Her interests extend also to subsequent outcomes, including myocardial infarction and percutaneous coronary intervention. Dr Best's ongoing clinical studies include the following:

- Does Chronic Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function in Nondiabetic Patients With Chronic Kidney Disease?
- Differences in Epicardial Plaque and Microvascular Function in Women With an Acute Myocardial Infarction
- Coronary Artery Microvascular Dysfunction in Women: A Genomic Approach to the Problem



### SELECTED PUBLICATIONS

Best PJM, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR Jr, Berger PB. The impact of renal insufficiency on clinical outcomes in patients after percutaneous coronary interventions. *J Am Coll Cardiol* 2002;39:1113-1119.

Szczzech LA, Best PJM, Crowley EM, Brooks MM, Berger PB, Bittner V, Gersh BJ, Jones R, Califf RM, Ting HH, Whitlow PJ, Detre KM, Holmes DR Jr. Outcomes of patients with chronic renal insufficiency in the Bypass Angioplasty Revascularization Investigation. *Circulation* 2002;105:2253-2258.

Herrmann J, Best PJM, Holmes DR Jr, Ritman EL, Richardson DM, Lerman LO, Lerman A. Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. *J Am Coll Cardiol* 2002;39:1555-1561.

Best PJM, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, Herzog CA, Holmes DR Jr, Berger PB. The safety of abciximab in patients with chronic renal insufficiency undergoing percutaneous coronary interventions. *Am Heart J* 2003;146:345-350.

Best PJM, Berger PB, Davis BR, Grines CL, Sadeghi HM, Williams B, Willerson JT, Granett JR, Holmes DR Jr. Impact on the frequency of restenosis in patients with mild or moderate chronic kidney disease: results from the PRESTO trial. *J Am Coll Cardiol* 2004;44:1786-1791.



## AMIR LERMAN, MD

The broad objective of Dr Lerman's research program is the detection, prevention, and treatment of early coronary atherosclerosis from cells to patient populations. The major focus of the program is on the role of the endothelium in the regulation of vascular tone in health and in disease and the role of the endothelium as well as the endothelial-derived factors and cells in vascular injury and repair.

The program is divided into several areas. The first part is focused on the basic mechanisms and animal studies. In this area, Dr Lerman is using animal models of early atherosclerosis such as hypercholesterolemic, hypertensive, and combined hypertensive/hypercholesterolemic pigs. Animal studies are done in vivo and in vitro to elucidate the role of the endothelium in regulation of vascular tone in coronary perfusion in these animal models.

The second part of the program is translation of these findings to human studies. This work is supported by the National Institutes of Health, the American Heart Association, and the US Department of Defense. It is focused on the role of the endothelium in the regulation of coronary vascular tone in humans.



Patients who are undergoing comprehensive evaluation of coronary blood flow, coronary vascular resistance, and coronary endothelial function in the cardiac catheterization laboratory have the opportunity to participate in various studies. New physiologic technology such as Doppler pressure and combined pressure flow wires as well as novel imaging techniques such as intravascular ultrasound, virtual histology, and intravascular magnetic resonance imaging are integrated into the program. Currently, several randomized studies are under way to address the role of the endothelial progenitor cells in vascular injury and repair in these patients.

### SELECTED PUBLICATIONS

Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. *Circulation* 2007;115:2715-2721.

Gössl M, Lerman A. Endothelin: beyond a vasoconstrictor. *Circulation* 2006;113:1156-1158.

Herrmann J, Lerman LO, Lerman A. Ubiquitin and ubiquitin-like proteins in protein regulation. *Circ Res* 2007;100:1276-1291.

## MARTIN G. RODRIGUEZ-PORCEL, MD

Cardiac cell therapy has appeared as a powerful therapeutic alternative for the treatment of different stages of coronary artery disease. However, many questions regarding the biology of these therapies remain unanswered. Molecular imaging provides a unique opportunity to address these critical questions noninvasively.


Work in Dr Rodriguez-Porcel's laboratory focuses on the use of molecular imaging modalities (eg, optical imaging, positron emission tomography, ultrasound) to better understand the biology of cardiac stem cells for cardiovascular applications. He concentrates on understanding the biological mechanisms underlying survival, proliferation, and differentiation of stem cells. Additionally, he has an interest in the use of molecular imaging to noninvasively assess atherosclerosis and its consequences.

### SELECTED PUBLICATIONS

Rodriguez-Porcel M, Gheysens O, Chen IY, Wu JC, Gambhir SS. Image guided cardiac cell delivery using small animal ultrasound. *Mol Ther* 2005;12:1142-1147.

Gheysens O, Lin S, Cao F, Wang D, Chen IY, Rodriguez-Porcel M, Min JJ, Gambhir SS, Wu JC. Noninvasive evaluation of immunosuppressive drug efficacy on acute donor cell survival. *Mol Imaging Biol* 2006;8:163-170.

Rodriguez-Porcel M, Brinton TJ, Gheysens O, Chen IY, Ikeno F, Wu JC, Yock PG, Gambhir SS. Percutaneous delivery and non-invasive imaging of gene and cell therapy in a porcine model. *J Nucl Med* 2006;47 (Suppl 1):73P.



## GURPREET S. SANDHU, MD, PhD

Dr Sandhu is an interventional cardiologist with his PhD in molecular biology. His research interests include novel cardiovascular device development, translational research in cell and gene targeting, creation of gene knock-out models, and development of cell coated synthetic grafts and rapidly healing stents.

Present funding for his research includes grants from the Sullivan Foundation, the American Heart Association, and the National Heart, Lung, and Blood Institute.




### SELECTED PUBLICATIONS

Pislaru SV, Harbuzariu A, Gulati R, Witt T, Sandhu NP, Simari RD, Sandhu GS. Magnetically targeted endothelial cell localization in stented vessels. *J Am Coll Cardiol* 2006;48:1839-1845.

Pislaru SV, Harbuzariu A, Agarwal G, Witt T, Gulati R, Sandhu NP, Mueske C, Kalra M, Simari RD, Sandhu GS. Magnetic forces enable rapid endothelialization of synthetic vascular grafts. *Circulation* 2006;114:I-314-I-318.

Sandhu G, Doyle B, Singh R, Bell M, Bresnahan J, Mathew V, Holmes D, Lerman A, Rihal C. Frequency, etiology, treatment, and outcomes of drug-eluting stent thrombosis during one year of follow-up. *Am J Cardiol* 2007;99:465-469.



## GARVAN C. KANE, MD, PhD

The emphasis of Dr Kane's work is deciphering mechanisms of cardiovascular stress tolerance with a particular focus on pulmonary hypertension, cardiac function, and heart failure from the animal to population level. Cardiac adaptation to imposed stress is critical for organ and host survival with maladaptive processes underlying pathologic disease states, including pulmonary arterial hypertension and congestive heart failure. Prior studies have elucidated critical proteins in the cardiovascular stress response that, through integration with central metabolic cellular pathways, facilitate optimal stress adaptation through orchestration of ionic and energetic balance. Specifically, a membrane metabolic sensor, the ATP-sensitive potassium channel that assimilates changes in cellular energetic status with membrane excitability was found to be vital in the cardiovascular response to hemodynamic stressors, including systemic hypertension and the systemic sepsis response. Such studies form the basis of ongoing investigation of novel potential therapeutic targets for these diseases. Current work focuses on the syndrome of pulmonary arterial hypertension, typified by pathogenic abnormal vascular remodeling and a maladaptive myocardial response, which invariably dictates the outcome in patients with pulmonary hypertension. Understanding homeostatic pathways in the pulmonary vasculature and right ventricular myocardium under (patho) physiologic stress will provide novel targets for pulmonary vascular therapeutics.



### SELECTED PUBLICATIONS

Kane GC, Behfar A, Yamada SY, Perez-Terzic C, O'Coilain F, Reyes S, Dzeja PP, Miki T, Seino S, Terzic A. KATP channel knockout compromises metabolic benefit of exercise training resulting in cardiac deficits. *Diabetes* 2004;53:S168-S175.

Kane GC, Liu X, Yamada S, Olson TM, Terzic A. Cardiac KATP channels in health and disease. *J Mol Cell Cardiol* 2005;38:937-943.

Kane GC, Behfar A, O'Coilain F, Dyer RB, Liu XK, Hodgson DM, Reyes S, Miki T, Seino S, Terzic A. KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension. *Hum Mol Genet* 2006;15:2285-2297.

Yamada S, Kane GC, Behfar A, Liu XK, Miki T, Seino S, Terzic A. Cardiac KATP channels protect against pressure overload induced heart failure. *J Physiol* 2006;577:1053-1065.

Kane GC, Lam CF, O'Coilain F, Hodgson DM, Reyes S, Liu XL, Miki T, Seino S, Katusic ZS, Terzic A. Gene knockout of the KCNJ8-encoded Kir6.1 KATP channel imparts fatal susceptibility to endotoxemia. *FASEB J* 2006;20:2271-2280.

## LESLIE T. COOPER, MD

Dr Cooper's investigations focus on clinical and translational studies of myocarditis and large vessel vasculitis. He directed the multicenter Giant Cell Myocarditis Treatment Trial and registry and has performed clinical trials of immunomodulation and immunoadsorption for acute and chronic nonischemic dilated cardiomyopathy. He is currently the principal investigator at Mayo for the National Institutes of Health study "The Genetic Basis of Left Ventricular Recovery." Current investigations focus on novel tissue and serum proteomic markers, including circulating autoantibody profiles. Dr Cooper is also the codirector of the Gonda Vascular Center Vasculitis Clinic.



### SELECTED PUBLICATIONS

Cooper LT, Berry GJ, Shabetai R. Idiopathic giant cell myocarditis: natural history and treatment. *N Engl J Med* 1997;336:1860-1866.

Okura Y, Dec GW, Hare JM, Kodama M, Berry GR, Tazelaar HD, Bailey KR, Cooper LT. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. *J Am Coll Cardiol* 2003;41:322-328.

Murphy JG, Wright RS, Bruce GK, Baddour LM, Farrell MA, Edwards WD, Kita H, Cooper LT. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. *Lancet* 2003;362:1378-1380.

Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, Ballman KV. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). *J Am Coll Cardiol* 2004;21;44:2410-2411.

Cooper LT, Belohlavek M, Korinek J, Yoshifuku S, Sengupta PP, Burgstaler EA, Winters JL. A pilot study to assess the use of protein A immunoadsorption for chronic dilated cardiomyopathy. *J Clin Apher* 2007;22:210-214.

## RICK A. NISHIMURA, MD

Dr Nishimura's research interests concern cardiac hemodynamics. His current work includes the evaluation of diastolic function using both invasive and noninvasive approaches. He is seeking to understand the mechanisms by which patients develop elevated filling pressures and potential treatment mechanisms.

Dr Nishimura has a longstanding interest in the hemodynamic consequences of hypertrophic cardiomyopathy. Current protocols include those evaluating the effect of clinical interventions on the natural history of the disease.



### SELECTED PUBLICATIONS

Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, Ackerman MJ. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. *Mayo Clin Proc* 2006;81:459-467.

Ling LH, Christian RF, Mulvagh SL, Klarich KW, Hauser MF, Nishimura RA, Pellikka PA. Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography. *Am Heart J* 2006;151:882-889.

Sorajja P, Nishimura RA, Ommen SR, Ackerman MJ, Tajik AJ, Gersh BJ. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. *J Am Soc Echocardiogr* 2006;19:788-795.

Mahapatra S, Nishimura RA, Oh JK, McGoon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr* 2006;19:1045-1050.

Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CX, Schaff HV, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 2007;49:350-357.

## STEVE R. OMMEN, MD

Dr Ommen's research efforts focus on the clinical aspects of the management of hypertrophic cardiomyopathy (HCM). Mayo Clinic has a longstanding history of treating HCM dating back nearly 5 decades and has the largest clinical database of HCM patients in the world. Current research efforts include further elucidation of pathophysiology involving both invasive and noninvasive hemodynamic assessment, evaluation of autonomic function, and electrophysiologic and demographic determinants of sudden cardiac death. Dr Ommen's work is also focused on assessment of the natural history of HCM, with particular focus on subsets of HCM, a disease that is notable for its vast heterogeneity in clinical expression.

Mayo Clinic's Cardiomyopathy Clinic has long been recognized as leader in the management of left ventricular outflow tract obstruction, a feature present in approximately 70% of HCM patients. The group strives to study and report the outcomes of surgical and nonsurgical treatment modalities and to continue to refine optimal patient selection criteria for various therapeutic modalities. Working in tandem with the Windland Smith Rice Sudden Death Genomics Laboratory at Mayo Clinic Rochester, Dr Ommen has a keen interest in the genetic underpinnings of HCM, how genetics influence each of the other aspects already mentioned, and most importantly, how understanding genetics translates into the care of each individual patient.



### SELECTED PUBLICATIONS

Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal SS, Schaff HV, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2007;49:350-357.

McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. *Eur Heart J* 2007;28:2583-2588.

Binder JA, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, Ackerman MJ. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septa morphological features predict the presence of myofilament mutations. *Mayo Clin Proc* 2006;81:459-467.

Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2005;46:470-476.

Ackerman MJ, Van Driest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, Gersh BJ. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. *J Am Coll Cardiol* 2002;39:2042-2048.

## XIAOLEI XU, PHD

The mission of the Zebrafish Genetic Laboratory is to use the power of genetics and genomics to gain insights into the molecular mechanisms of human heart diseases. Ongoing projects include efforts to establish embryonic zebrafish models for studying cardiac remodeling and congenital heart diseases as well as cardiomyopathy and heart failure.

In the laboratory, Dr Xu and colleagues combine bioinformatics and comparative genomics to help determine which genes are of interest for studies related to human heart diseases. These “in silico” analyses are followed up with in vivo experiments using morpholino-mediated reduction in gene expression, transgenic zebrafish, and insertional mutagenesis screening to help determine the functions of the encoded proteins. The ultimate goal of these studies is to perform mutagenesis or small-molecule screens using zebrafish models to identify novel therapeutic strategies or drugs for the treatment of congenital heart diseases and heart failure.



### SELECTED PUBLICATIONS

Xu X, Meiler SE, Zhong TP, Mohideen M, Crossley DA, Burggren WW, Fishman MC. Cardiomyopathy in zebrafish due to mutation in an alternatively spliced exon of titin. *Nat Genet* 2002;30:205-209.

Bos JM, Poley RN, Ny M, Tester DJ, Xu X, Vatta M, Towbin JA, Gersh BJ, Ommen SR, Ackerman MJ. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. *Mol Genet Metab* 2006;88:78-85.

Seeley M, Huang W, Chen Z, Wolff WO, Lin X, Xu X. Depletion of zebrafish titin reduces cardiac contractility by disrupting the assembly of Z-discs and A-bands. *Circ Res* 2007;100:238-245.

Lin X, Rinaldo L, Fazly AF, Xu X. Depletion of Med10 enhances Wnt and suppresses nodal signaling during zebrafish embryogenesis. *Dev Biol* 2007;303:536-548.

Rich A, Leddon S, Gibbons SJ, Miller SM, Xu X, Farrugia G. Kit-like immunoreactivity in the zebrafish gastrointestinal tract reveals putative ICC. *Dev Dyn* 2007;236:903-911.



## SUDHIR S. KUSHWAHA, MD

Dr Kushwaha's research has been focused on coronary physiology of the transplanted heart and strategies for the prevention of cardiac allograft vasculopathy. He has initiated the use of sirolimus as primary immunosuppression for cardiac transplant recipients for the purpose of preservation of renal function and attenuation of allograft vasculopathy. Using intracoronary ultrasound attenuation of coronary intimal proliferation has been demonstrated in cardiac transplant recipients treated with sirolimus.

Ongoing studies include assessment of endothelial function in cardiac transplant recipients converted to sirolimus and comparing them with patients on standard cyclosporine-based immunosuppression; factors contributing to the development of allograft vasculopathy; and left ventricular remodeling after cardiac transplantation. Among Dr Kushwaha's other research interests are diastolic dysfunction and pulmonary hypertension and the use of left ventricular assist devices for the treatment of end-stage heart failure.



### SELECTED PUBLICATIONS

Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. *N Engl J Med* 1997;336:267-376.

Kushwaha SS, Narula J, Narula X, Zervos G, Semigran S, Fischman A, Alpert N, Dec GW, Gewirtz H. Natural history of changes in myocardial blood flow and microvascular dilator capacity in humans following orthotopic cardiac transplantation: observations in patients with normally functioning allografts. *Am J Cardiol* 1998;82:1377-1381.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. *J Heart Lung Transplant* 2005;24:2129-2136.

Puri A, McGoan MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. *Nat Clin Pract Cardiovasc Med* 2007;4:319-329.

Raichlin E, Khalpey Z, Kremers WK, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS. Replacement of calcineurin inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. *Transplantation* 2007;84:467-474.

## HORNG H. CHEN, MB, BCH

The focus of his research has been the local and circulating neurohormonal systems that contribute to heart failure and the development of novel therapeutic and diagnostic strategies. Dr Chen has successfully completed laboratory studies looking at the natriuretic peptides, vasopeptidase inhibitors, endothelin, the renin-angiotensin-aldosterone system, and adrenomedullin in congestive heart failure. More importantly, he has translated these laboratory studies to clinical studies where new therapeutic potential for the treatment and possible prevention of heart failure is being applied. He is a project leader on a program project grant, "Biology and Therapeutics of Cardiovascular Peptides in Disease." Dr Chen's project concerns the cardiorenal physiology and experimental therapeutics of stage B human heart failure.



### SELECTED PUBLICATIONS

Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal responses to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. *Circulation* 1999;100:2443-2448.

Chen HH, Grantham JA, Schirger JA, Redfield MM, Burnett JC Jr. Subcutaneous administration of brain natriuretic peptide (BNP) in experimental heart failure. *J Am Coll Cardiol* 2000;36:5:1706-1712.

Chen HH, Lainchbury JG, Harty JH, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous BNP and acute vasopeptidase inhibition. *Circulation* 2002;105:999-1003.

Chen HH, Redfield MM, Cataliotti A, Burnett JC Jr. Angiotensin AT1 receptor antagonism prevents the detrimental renal actions of acute diuretic therapy in human heart failure. *Am J Physiol Renal Physiol* 2003;284:F115-F119.

Chen HH, Redfield MM, Horton D, Nordstrom LJ, Burnett JC Jr. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. *J Card Fail* 2004;10:115-119.



## BARRY A. BORLAUG, MD

Dr Borlaug's research focuses on the pathophysiologic mechanisms causing heart failure, specifically heart failure with preserved systolic function (often referred to as "diastolic heart failure"). This disease affects about half of all Americans with heart failure, particularly older patients and women, and there is no proven treatment. Achieving a greater understanding of what causes these patients' symptoms and disability may help health care providers better define optimal treatment strategies.

Dr Borlaug's active studies in patients with heart failure with preserved systolic function are examining the impact of increased vascular stiffening on cardiac functional reserve and exercise performance and performing gold standard invasive hemodynamic assessment of ventricular systolic and diastolic performance at rest and during the acute stress of exercise in the cardiac catheterization laboratory. Increased vascular stiffening is a part of normal aging but seems to be accelerated in patients with hypertensive heart disease, diabetes, kidney disease, and heart failure. He is additionally pursuing research examining the effects of vascular stiffening and pressure wave reflections on symptoms and functional capacity in patients with heart failure with mildly depressed systolic function.

### SELECTED PUBLICATIONS

Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. *Circulation* 2006;114:2138-2147.

Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. *Circulation* 2005;112:2642-2649.


Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. *Circulation* 2005;112:2254-2262.

Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. *J Am Coll Cardiol* 2007;49:198-207.

Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. *Circulation* 2007;115:1982-1990.

## LYLE J. OLSON, MD

Dr Olson's broad research interest is cardiopulmonary interactions in heart failure. His research goals include continued commitment to prospective, mechanistic, patient-oriented research focused on ventilatory control in human heart failure. Ongoing and future studies will investigate the regulation of breathing at rest, during exercise, and with sleep to clarify the interaction between cardiac dysfunction and the ventilatory control system in the pathogenesis of periodic breathing. This work may lead to advances in clinical practice, including new methods for the screening and detection of sleep-disordered breathing in patients with heart failure and for surveillance of heart failure decompensation.



### SELECTED PUBLICATIONS

Wolk R, Johnson BD, Somers VK, Allison TG, Squires RW, Gau GT, Olson LJ. Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure. *J Card Fail* 2005;11:333-339.

Olson LJ, Snyder EM, Beck KC, Johnson BD. Reduced rate of alveolar-capillary recruitment and fall of pulmonary diffusing capacity during exercise in patients with heart failure. *J Card Fail* 2006;12:299-306.

Olson LJ, Arruda-Olson AM, Somers VK, Scott CG, Johnson BD. Exercise oscillatory ventilation: instability of breathing control associated with advanced heart failure. *Chest* 2008;133:474-481.

## JOHN C. BURNETT, JR, MD

Dr Burnett is the Marriott Family Cardiovascular Research Professor and director of the Cardiorenal Research Laboratory. His research is focused on the heart as an endocrine organ with a special emphasis on integration of the heart and kidney in cardiorenal homeostasis. A special focus is on the cardiac natriuretic peptide system in cardiorenal regulation as it relates to the pathobiology, novel diagnostics, and innovative therapeutics of heart failure, hypertension, and acute myocardial infarction. With a long history of funding by the National Institutes of Health, his research group has demonstrated in cell systems, animal models, and humans that these peptides of cardiovascular origin may preserve cardiorenal structure and function via the second messenger cGMP in cardiovascular disease.

His group has elucidated mechanisms that mediate resistance to natriuretic peptides using state-of-the-art mass spectrometry and cell biology. Studies reveal altered molecular forms of the native natriuretic peptides with reduced biological actions that mediate resistance to native circulating natriuretic peptides and thus contributing to the clinical phenotype of heart failure and hypertension.

Most recently, Dr Burnett's laboratory has designed and synthesized novel new-generation natriuretic peptides as well as novel delivery systems, making them orally available. To complement targeting particulate guanylyl cyclases and cGMP with the natriuretic peptides, the group is also targeting soluble guanylyl cyclase (sGC) and cGMP signaling with highly innovative direct sGC agonists, representing an additional new paradigm in cardiovascular therapeutics. These molecules are now in clinical trials and offer an exciting new possibility for therapeutic use of the natriuretic peptides.

Finally, integrating the strategy of novel drugs based on the natriuretic peptides, the laboratory is engaged in the new field of theragnostics. Here they



are developing innovative genetic, protein, and imaging biomarkers that will aid in identifying patients with early cardiorenal disease that would benefit from natriuretic peptide therapy. This area will represent a new strategy for individualizing protein therapy in preventing and delaying the progression of cardiovascular disease.

### SELECTED PUBLICATIONS

Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr. Oral human BNP activates cGMP and decreases mean arterial pressure. *Circulation* 2005;112:836-840.

Hawkridge AM, Heublein D, Bergen HR, Cataliotti A, Burnett JC Jr, Muddimun DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. *Proc Natl Acad Sci U S A* 2005;102:17442-17447.

Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. *J Am Coll Cardiol* 2006;217:47:345-353.

McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and BNP: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertension* 2006;47:874-880.


Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. *Hypertension* 2007;49:1128-1133.

## MARGARET M. REDFIELD, MD

Dr Redfield's research program includes laboratory-based translational and preclinical research, clinical research, and population-based studies. Her broad area of interest is heart failure. Specific areas of focus include

- the epidemiology, pathophysiology, and therapeutics of diastolic heart failure
- the epidemiology, pathophysiology, and therapeutics of cardiovascular failure
- the natriuretic peptides
- device therapy of systolic heart failure

Dr Redfield is director of the Mayo Heart Failure Clinical Program, codirector of the Mayo Cardiorenal Research Laboratory, and codirector of Mayo's NIH Cardiovascular Research Training Program. The heart failure program at Mayo Clinic is 1 of the 9 in the NIH Heart Failure Clinical Research Network. Her program is funded by the National Institutes of Health and Mayo Clinic.



### SELECTED PUBLICATIONS

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med* 2006;355:251-259.

Lam CSP, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. *Circulation* 2007;115:1982-1890.

Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 2003;289:194-202.

Munagala VK, Hart CYT, Burnett JC Jr, Meyer DM, Redfield MM. Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. *Circulation* 2005;111:1128-1135.

Patel JB, Valencik ML, Pritchett AM, Burnett JC Jr, McDonald JA, Redfield MM. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. *Am J Physiol Heart Circ Physiol* 2005;289:H777-H784.

## ROBERT P. FRANTZ, MD

Dr Frantz is director of the Mayo Pulmonary Hypertension Clinic and the Cardiovascular Studies Unit. His research interests include neurohumoral activation and biomarkers and prognostic modeling in heart failure and pulmonary hypertension. He is co-investigator on a National Institutes of Health grant that includes catheterization laboratory-based investigation of genetic determinants of exercise hemodynamics and pulmonary limitations in heart failure. He is also conducting high-altitude research, including effects of sildenafil versus acetazolamide on cardiopulmonary physiology under hypoxic conditions. He is principal investigator on numerous trials of investigational therapies for pulmonary hypertension, including orally bioavailable prostanoids.

Additionally, he is studying the role of implantable hemodynamic monitors in guiding therapy and understanding physiology in pulmonary hypertension and congestive heart failure. As a member of the cardiac transplant and advanced heart failure program, he is collaborating on studies of the genomic and proteomic response to left ventricular assist device implantation. He is also conducting research on the role of metabolic syndrome and inflammatory markers on the risk of coronary allograft vasculopathy.



### SELECTED PUBLICATIONS

Frantz RP, Lowes BD, Grayburn PA, White M, Krause-Steinrauf H, Krishnan V, Uyeda L, Burnett JC; BEST Neurohumoral Substudy Investigators. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). *J Card Fail* 2007;13:437-444.

Raichlin RE, McConnell JP, Lerman A, Edwards BS, Kushwaha SS, Clavell AL, Rodeheffer RJ, Frantz RP. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. *J Heart Lung Transplant* 2007;26:826-833.

Karamanoglu M, McGoon M, Frantz RP, Benza RL, Bourge RC, Barst RJ, Kjellstrom B, Bennett TD. Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. *Chest* 2007;132:37-43.

Olson TP, Frantz RP, Snyder EM, O'Malley KA, Beck KC, Johnson BD. Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. *Am Heart J* 2007;153:104.e1-104.e7.

Olson TP, Snyder EM, Frantz RP, Turner ST, Johnson BD. Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. *Am Heart J* 2007;153:426-432.

## CARMEN M. TERZIC, MD, PhD

The major barrier in the treatment of cardiovascular disease is the inability of the myocardium for self-renewal. On the basis of the emerging principle that replacement of injured tissue by healthy tissue could rescue a failing phenotype, Dr Terzic's laboratory has focused on developing a stem cell-based strategy to repair diseased cardiac tissue. She has been able to direct embryonic stem cells toward cardiogenesis and optimize their properties for cardiac commitment. Dr Terzic has developed techniques by which direct injection of embryonic stem cells in a murine model of cardiac infarction engrafts and repopulates the diseased heart with cardiac cells derived from the embryonic stem cells. The ultimate goal is to establish cardiovascular regenerative medicine as a new therapeutic modality for heart disease.

Dr Terzic also uses embryonic stem cells to study cardiac cell differentiation and the role of nuclear transport. Transport across the nuclear envelope is vital, and deficiency in the nuclear localization of transcription factors has been related to congenital abnormalities, including cardiac defects. A case in point is the lethal defect in cardiac development described recently in embryos lacking calreticulin, a multifunctional calcium-binding chaperone protein. The mechanisms responsible for calreticulin-mediated regulation of nuclear function and the contribution of calreticulin in cardiogenesis are poorly understood. Dr Terzic has established a stem cell-based model of calreticulin gene knockout (*crt*<sup>-/-</sup>) and obtained data suggesting a contribution of calreticulin in securing the structural and functional competence of nuclear pores and therefore differentiation. Using state-of-the-art techniques, including laser confocal microscopy, atomic force microscopy, proteomic and genomic analysis, gene transfection, and point mutation, she has obtained insight into molecular events associated with nucleocytoplasmic communication critical for cardiovascular differentiation.



### SELECTED PUBLICATIONS

Perez-Terzic C, Pyle J, Jaconi M, Stehno-Bittel L, DE Clapham. Conformational states of the nuclear pore complex induced by depletion of the nuclear calcium stores. *Science* 1996;273:1875-1877.

Perez-Terzic C, Faustino RS, Boorsma BJ, Arrell DK, Niederlander NJ, Behfar A, Terzic A. Stem cell transformation into cardiac phenotype guided by directed remodeling of nuclear transport machinery. *Nat Clin Prac Cardiovasc Med* 2007;4:S68-S76.

Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM, Yamada S, Pucéat M, Niederlander NJ, Alekseev AE, Zingman LV, Terzic A. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. *J Exp Med* 2007;204:405-420.

Faustino RS, Terzic A, Nelson T, Perez-Terzic C. Nuclear transport: target for therapy. *Clin Pharmacol Ther* 2007;81:880-886.



## RICHARD J. L. RODEHEFFER, MD

The focus of Dr Rodeheffer's research has been on the epidemiology of cardiac structure and function in community populations. The goal has been to provide foundational data on the distribution of ventricular function parameters in naturally occurring populations and to assess the relationship between ventricular structure and function and symptoms of cardiovascular disease. The longitudinal study of 2,000 randomly chosen Olmsted County residents has allowed for analysis of changes in cardiac structure and function over time and has provided important information on changes in circulatory physiology that increase the risk of future congestive heart failure.



### SELECTED PUBLICATIONS


Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. The burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 2003;289:194-202.

Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. *Circulation* 2004;109:3176-3181.

Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. *Circulation* 2005;112:2254-2262.

Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the community. *Circulation* 2007;115:1563-1570.

Lam CSP, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. *Circulation* 2007;115:1982-1990.



## PANITHAYA CHAREONTHAITAWEE, MD

The focus of her research is the application of positron emission tomography (PET) imaging techniques to address pathophysiologic mechanisms of disease and the effects of interventions and therapies on these mechanisms. Currently available cardiac PET techniques include absolute quantification of myocardial blood flow and flow reserve, myocardial glucose utilization, myocardial oxidative metabolism, and cardiac sympathetic function. Her additional research focuses on the diagnostic and prognostic value of clinical PET and single-photon emission computed tomography (SPECT) studies. Her research efforts have been funded by peer-reviewed awards from Mayo Clinic, the American Heart Association, and the American Society of Nuclear Cardiology.

### SELECTED PUBLICATIONS

Chareonthaitawee P, Somers V. Continuous positive airway pressure and increased ejection fraction in heart failure and obstructive sleep apnea: is there a metabolic cost or benefit? *J Am Coll Cardiol* 2007;49:459-460.

Chareonthaitawee P, Christenson SD, Rihal CS, Hodge DO, Kemp BJ, Gibbons RG, Frye RL. Whole-body and myocardial insulin resistance in type 2 diabetes mellitus and established coronary artery disease: a BARI 2D positron emission tomography substudy. *J Am Coll Cardiol* 2007;49:147A.

Chareonthaitawee P, Christenson SD, Allen JL, Kemp BJ, Hodge DO, Ritman EL, Gibbons RJ. Reproducibility of measurements of regional myocardial blood flow in a model of coronary artery disease: comparison of H<sub>2</sub><sup>15</sup>O and <sup>13</sup>NH<sub>3</sub> PET techniques. *J Nucl Med* 2006;47:1193-1201.

Bybee KA, Murphy J, Prasad A, Wright RS, Lerman A, Rihal CS, Chareonthaitawee P. Acute impairment of regional myocardial glucose metabolism in the transient left ventricular apical ballooning (Takotsubo) syndrome. *J Nucl Cardiol* 2006;13:244-250.

Sorajja P, Chareonthaitawee P, Rajagopalan N, Miller TD, Frye RL, Hodge DO, Gibbons RJ. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. *Circulation* 2005;112:I311-I316.

## RAYMOND J. GIBBONS, MD

Dr Gibbons is a senior investigator in nuclear cardiology and myocardial infarction with more than 275 peer-reviewed publications. His recent work in nuclear cardiology has focused on the clinical value of single-photon emission computed tomography (SPECT) perfusion imaging in particular patient subsets, eg, diabetic and elderly patients, as well as its role in clinical decision-making. The Nuclear Cardiology Laboratory has served as the core laboratory for SPECT perfusion images to measure the size of myocardial infarction in more than 20 multicenter randomized trials. Recent publications from this work have reported the primary end points from these trials, as well as the results of substudies focusing on the post-hoc analysis of patient subsets, eg, diabetic patients. Most recently, Dr Gibbons has initiated a new effort in clinical research focused on the appropriateness of imaging and the proper application of published appropriateness criteria to clinical practice. The nuclear cardiology research effort that Dr Gibbons directs has been well funded by external grants for the past 15 years. The resources from these grants are available to support well-designed clinical research studies.



### SELECTED PUBLICATIONS

Valeti US, Miller TD, Hodge DO, Gibbons RJ. Exercise single photon emission computed tomography effectively risk stratifies elderly men and elderly women. *Circulation* 2005;111:1771-1776.

Sorajja P, Chareonthaitawee P, Rajagopalan N, Miller TD, Frye RL, Hodge DO, Gibbons RJ. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. *Circulation* 2005;112(9 Suppl S):1311-1316.

Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, Lansky AJ, Mehran R. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA* 2005;293:1063-1072.

Brindis RG, Douglas PS, Hendel RC, Peterson ED, Wolk MJ, Allen JM, Patel MR, Raskin IE, Hendel RC, Bateman TM, Cerqueira MD, Gibbons RJ, Gillam LD, Gillespie JA, Hendel RC, Iskandrian AE, Jerome SD, Krumholz HM, Messer JV, Spertus JA, Stowers SA; American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group; American Society of Nuclear Cardiology; American Heart Association. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. *J Am Coll Cardiol* 2005;46:1587-1605.

## JAE K. OH, MD

Dr Oh's primary research interest is to explore clinical applications of echocardiography and its use in clinical trials. He combines his clinical interest in acute coronary care, diastolic function, cardiac hemodynamics, heart failure, aortic dissection, and pericardial diseases with the use of echocardiography in those clinical fields. He is a member of the International Registry of Acute Aortic Dissection and is active in echocardiographic education for health care providers at all levels.

Specific current research activities include

- Management and clinical outcome of patients with acute and relapsing pericarditis
- Tissue Doppler and strain imaging in cardiac resynchronization therapy and cardiac function
- Use of echocardiography in patients with acute myocardial infarction
- Evaluation of diastolic function by echocardiography at rest and exercise
- Mayo Clinic Core Echocardiography Laboratory for various clinical trials



### SELECTED PUBLICATIONS

Ha JW, Oh JK, Ling LH, Nishimura RA, Seward JB, Tajik AJ. Annulus paradoxus: transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary wedge pressure in patients with constrictive pericarditis. *Circulation* 2001;104:976-978.

Talreja DR, Edwards WD, Danielson GK, Schaff HV, Tajik AJ, Tazelaar HD, Breen JF, Oh JK. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. *Circulation* 2003;108:1852-1857.

Hillis GS, Moller JE, Pellikka PA, Gersh BJ, Wright RS, Ommen SR, Reeder GS, Oh JK. Noninvasive estimation of left ventricular filling pressure by  $E/e'$  is a powerful predictor of survival after acute myocardial infarction. *J Am Coll Cardiol* 2004;43:360-367.

Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. *J Am Coll Cardiol* 2006;47:500-506.

Hillis GS, Zehr KJ, Williams AW, Schaff HV, Orszulak TA, Daly RC, Mullany CJ, Rodeheffer RJ, Oh JK. Outcome of patients with low ejection fraction undergoing coronary artery bypass grafting: renal function and mortality after 3.8 years. *Circulation* 2006;114(Suppl 1):I414-I419.

Acker MA, Bolling S, Shemin R, Kirklin J, Oh JK, Mann DL, Jessup M, Sabbah HN, Starling RC, Kubo SH. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. *J Thorac Cardiovasc Surg* 2006;132:568-577.

## PATRICIA A. PELLIKKA, MD

Dr Pellikka's research is focused on the application of echocardiography and stress testing to the early detection of heart disease and for assessment of prognosis. The echocardiography laboratory annually performs more than 50,000 clinical transthoracic and transesophageal echocardiographic studies and 8,000 stress echocardiographic studies and has an active research program involving multiple areas of investigation:

- The role of echocardiography, including novel methods such as myocardial perfusion, strain, tissue Doppler, and strain rate imaging in predicting outcomes in patients with coronary artery disease and myocardial disease is being evaluated.
- Three-dimensional echocardiography is being used to quantify cardiac chamber sizes and systolic function.
- Exercise Doppler echocardiography is being used to evaluate valvular heart disease and stress-related changes in diastolic function and the relationship of these findings to clinical outcome.
- Noninvasive ultrasound modalities, including carotid intima-media thickness measurement, brachial artery reactivity, and pulse wave tonometry, are being assessed as means of detecting preclinical cardiovascular disease.
- In patients with systemic amyloidosis, a large database has been accumulated and is being evaluated to determine early markers of cardiac involvement and predictors of outcome.
- In collaboration with colleagues from oncology, carcinoid heart disease is being studied



with clinical and translational models in an effort to identify means of preventing disease progression.

- Age- and sex-related changes in cardiac structure and function are being evaluated.

Funding is currently provided by Mayo Clinic.

### SELECTED PUBLICATIONS

Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. *N Engl J Med* 2003;348:1005-1015.

Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. *Circulation* 2005;111:3290-3295.

Chaowalit N, McCully RB, Callahan MJ, Mookadam F, Bailey KR, Pellikka PA. Outcomes after normal dobutamine stress echocardiography and predictors of adverse events: long-term follow-up of 3,014 patients. *Eur Heart J* 2006;27:3039-3044.

Bergeron S, Moller JE, Bailey KR, Chen HH, Burnett JC, Pellikka PA. Exertional changes in circulating cardiac natriuretic peptides in patients with suspected coronary artery disease. *J Am Soc Echocardiogr* 2006;19:772-776.

Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, Bailey KR, Wood CM, Movo S, Miyazaki C, Miller FA. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. *J Am Soc Echocardiogr* 2007; 20:1194-1202.

## J. WELLS ASKEW, MD

Dr Askew's research is focused primarily in nuclear cardiology with an emphasis on the value of noninvasive stress testing in specific population subsets. Recent work has included the yield of myocardial perfusion imaging in asymptomatic patients with atrial fibrillation, the yield of myocardial perfusion imaging in asymptomatic patients with coronary artery calcium, and the accuracy of different radiolabeled tracers to measure myocardial blood flow by positron emission tomography.


### SELECTED PUBLICATIONS

Askew JW, Miller TD, Hodge DO, Gibbons RJ. The value of myocardial perfusion single-photon emission computed tomography in screening asymptomatic patients with atrial fibrillation for coronary artery disease. *J Am Coll Cardiol* 2007;50: 1080-1085.

Askew JW, Miller TD, Araoz PA, Breen JF, Hodge DO, Gibbons RJ. Abnormal electron beam computed tomography results: the value of repeating myocardial perfusion single-photon emission computed tomography in the ongoing assessment of coronary artery disease. *Mayo Clin Proc* 2008;83:17-22.

Askew JW, Christenson SD, Anderson JL, et al. Accuracy of regional myocardial blood flow measurements in a model of acute myocardial infarction with reperfusion: comparison N-13 ammonia and O-15 water positron emission tomography techniques to fluorescent microspheres. In press.

Askew JW, Christenson SD. Abnormalities on cardiac planar projection and tomographic images: focus on pericardial effusions. *Int J Cardiol* 2008;127:266-268.





## HECTOR R. VILLARRAGA, MD

Dr Villarraga's research interests include the use of echocardiographic imaging and Doppler echocardiography to evaluate cardiac physiology and pathophysiology. Ongoing protocols include the following:

- Velocity Vector Imaging for Assessment of Early Systolic Dysfunction in Valvular Heart Disease
- Left Atrial Strain and Strain Rate Study
- Aortic Tissue Velocity and Coronary Artery Blood Flow in Patients Treated With Enhanced External Counterpulsation
- Arterial Stiffness
- Velocity Vector Imaging: Are We Close to a Quantitative Approach to Evaluate Myocardial Deformation in Stress Echocardiography?
- Cardiac Allograft Remodeling After Heart Transplantation
- Evaluation of RV and RA Mechanics Using Novel Ultrasound Imaging Techniques
- Correlation Between the Severity of Diastolic Dysfunction and Cardiac Torsion
- Changes of Left Atrial Volume During Exercise Stress Echocardiography
- Evaluation of Strain and Strain Rate in Patients After Heart Transplant

## TODD D. MILLER, MD

The focus of Dr Miller's research is the application of nuclear myocardial imaging for the diagnosis and prognosis of coronary artery disease. The nuclear imaging techniques include stress single-photon emission computed tomographic (SPECT) imaging and quantitative infarct sizing.



### SELECTED PUBLICATIONS

Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomographic imaging. *J Am Coll Cardiol* 2005;45:43-49.

Valeti US, Miller TD, Hodge DO, Gibbons RJ. Exercise single-photon emission computed tomography provides effective risk stratification of elderly men and elderly women. *Circulation* 2005;111:1771-1776.

Miller TD, Roger VL, Hodge DO, Gibbons RJ. A simple clinical score accurately predicts outcome in a community-based population undergoing stress testing for evaluation of chronic coronary artery disease. *Am J Med* 2005;118:866-872.

Balaravi B, Miller TD, Hodge DO, Gibbons RJ. The value of stress single photon emission computed tomography in patients without known coronary artery disease presenting with dyspnea. *Am Heart J* 2006;152:551-557.



P H O E N I X /

S C O T T S D A L E

ARIZONA



## ARSHAD JAHANGIR, MD

Dr Jahangir has expertise in cardiac electrophysiology and gerontology and directs the CardioGerontology Research Laboratory. His basic research interests include the study of aging on cardiovascular pathophysiology, cardioprotection, and arrhythmogenesis, specifically focusing on the role of mitochondria in cardiac responsiveness to stress.

He has received several awards, including recent acknowledgment by the American Society for Clinical Pharmacology and Therapeutics, which presented him with the William B. Abrams Award for Geriatric Clinical Pharmacology. He has received research grants from the National Institute on Aging of the National Institutes of Health, the American Heart Association, and the Society of Geriatric Cardiology and several intramural awards from Mayo Clinic.

His CardioGerontology Research Laboratory studies the effect of aging on cardiac function in health and diseases and uses a multiparametric approach, applying tools from molecular biology, basic cardiac electrophysiology, imaging, pharmacology, genomics, and proteomics to study changes in heart function with aging. The focus is on transcriptional and proteomic profiling with detailed functional assessment of cellular and mitochondrial pathways regulating cardiac energetics, ion channels, and cellular excitability in animal models and cardiac tissue from young and elderly patients. The overall goal of his research is to obtain insights into the molecular basis for increased susceptibility of the aging heart to electrical instability and mechanical dysfunction and to discover novel therapeutics for the prevention and treatment of age-related cardiac disabilities.



### SELECTED PUBLICATIONS

Jahangir A, Sagar S, Terzic A. Aging and cardioprotection. *J Appl Physiol* 2007;103:2120-2128.

Preston CC, Oberlin AS, Holmuhamedov EL, Gupta A, Sagar S, Syed RH, Siddiqui SA, Raghavakaimal S, Terzic A, Jahangir A. Aging-induced alterations in gene transcripts and functional activity of mitochondrial oxidative phosphorylation complexes in the heart. *Mech Ageing Dev* 2008;129:304-312.

Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, Shen WK, Gersh BJ. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. *Circulation* 2007;115:3050-3056.

Sagar S, Jahangir A, Espinosa RE, Louwagie CR, Olson LJ. Cardiac resynchronization by restoration of native ventricular activation: reversal of iatrogenic mitral regurgitation and heart failure. *Circulation* 2008;117:2160-2161.

Cha YM, Friedman PA, Asirvatham SJ, Shen WK, Munger TM, Rea RF, Brady PA, Jahangir A, Monahan KH, Hodge DO, Meverden RA, Gersh BJ, Hammill SC, Packer DL. Catheter ablation for atrial fibrillation in patients with obesity. *Circulation* 2008;117:2583-2590.

**KOMANDOOR SRIVATHSAN, MD**  
**GREGORY T. ALTEMOSE, MD**  
**LUIS R.P. SCOTT, MD**

Embodying the team approach that is intrinsic to the Mayo Clinic Model of Care, Drs Srivathsan, Altemose, and Scott collaborate intensively on research projects designed to better diagnose, manage, and prevent atrial fibrillation and other cardiac rhythm abnormalities. Recent studies have centered on rhythm pacing, the effects of radiation exposure on pulmonary function, the predictors of outcome in cardiac resynchronization therapy (CRT), the effect of pacing polarity in CRT, and the usefulness of acoustic phonocardiography in CRT. The team is also investigating alternative methods of implanting and configuring medical devices such as cardiac defibrillators in patients with anatomic or functional abnormalities that prohibit conventional implantation, as well as researching tissue adhesive as a surgical closing technique. In addition, they are examining outcomes and predictors of outcomes in pulmonary vein ablation as techniques and technology continue to evolve. They are evaluating new antiarrhythmic drug therapies for atrial fibrillation, and they are studying new electrocardiographic criteria for the diagnosis of wide complex tachycardia.



#### SELECTED PUBLICATIONS

Srivathsan K, Bunch TJ, Asirvatham SJ, Edwards WD, Friedman PA, Munger TM, Hammill SC, Cha Y, Brady PA, Jahangir A, Bradley DJ, Rea RF, Packer DL, Shen W. Mechanisms and utility of discrete great arterial potentials in the ablation of outflow tract ventricular arrhythmias. *Circ Arrhythmia Electrophysiol* 2008;1:30-38.

Srivathsan K, Scott LR, Altemose GT. T-wave oversensing and inappropriate shocks: a case report. *Eurospace* 2008;10:552-555.


Yang HS, Srivathsan K, Wissner E, Chandrasekaran K. Real-time 3 dimensional transesophageal echocardiography: novel utility in atrial fibrillation ablation with a prosthetic mitral valve. *Circulation* 2008;8;117:e304-e305.

Srivathsan K, Gami AS, Barrett R, Monahan K, Packer DL, Asirvatham SJ. Differentiating atrioventricular nodal reentrant tachycardia from junctional tachycardia: novel application of the delta H-A interval. *J Cardiovasc Electrophysiol* 2008;19:1-6.

## CHRISTOPHER P. APPLETON, MD

Dr Appleton's research centers around new cardiac ultrasound imaging techniques used in the investigation of cardiac physiology. His interest includes a new ultrasound technique, 2-dimensional speckle tracking imaging, that allows physicians to examine the physiology of the heart muscle itself and determine very early on whether cardiac function is becoming abnormal, usually as a result of hypertension or diabetes. Such techniques are a new way to examine the contractile function of the heart and may prove more accurate than ejection fraction to predict and diagnose cardiac disease.

Dr Appleton also works with the liver transplant program to develop better ways to reduce cardiovascular morbidity and mortality before, during, and after liver transplant. Because hepatic dysfunction renders traditional biomarkers of risk indeterminate, new applications of modalities such as dobutamine stress echocardiography and carotid intima-media thickness testing are being evaluated as methods to reduce perioperative cardiovascular complications.



### SELECTED PUBLICATIONS

Nagueh SF, Appleton CP, Gillebert TC, Marino P, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. In press.

Umphrey LG, Hurst RT, Eleid MF, Ruess CS, Hentz JG, Vargas HE, Appleton CP. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. *Liver Transpl* 2008;14:886-892.

Al-Omari MA, Finstuen J, Appleton CP, Barnes ME, Tsang TS. Echocardiographic assessment of left ventricular diastolic function and filling pressure in atrial fibrillation. *Am J Cardiol* 2008;101:1759-1765.

Appleton CP. Evaluation of diastolic function by two-dimensional and Doppler assessment of left ventricular filling including pulmonary venous flow. In Klein AL, Garcia MJ, editors. *Diastology: Clinical Approach to Diastolic Heart Failure*. Philadelphia: Saunders/Elsevier; 2008:115-143.

## MAREK BELOHLAVEK, MD, PhD

Dr Belohlavek has established a program in translational ultrasound research with the goal of characterizing normal and dysfunctional cardiac function by echocardiographic imaging and computational models—advancing scientific understanding of heart physiology and facilitating the early detection and treatment of ischemic and other cardiac diseases. Focuses include the interaction between cardiac mechanical function and blood flow patterns inside the heart, as well as studies of how efficiently blood is transported within the heart. The program merges cardiac ultrasound imaging with multidimensional computer reconstruction of cardiac structure and mathematical analyses of cardiac mechanical function, heart muscle blood supply and intracardiac blood flow dynamics, with a main emphasis on ischemic heart disease and additional studies that involve experimental diagnostic tests and their translation to clinical use.



### SELECTED PUBLICATIONS

Belohlavek M, Foley DA, Gerber TC, Greenleaf JF, Seward JB. Three-dimensional ultrasound imaging of the atrial septum: normal and pathologic anatomy. *J Am Coll Cardiol* 1993;22:1673-1678.

Belohlavek M, Tanabe K, Jakrapanichakul D, Breen JF, Seward JB. Rapid three-dimensional echocardiography: clinically feasible alternative for precise and accurate measurement of left ventricular volumes. *Circulation* 2001;103:2882-2884.

Wang JW, Abraham TP, Korinek J, Urheim S, McMahon EM, Belohlavek M. Delayed onset of subendocardial diastolic thinning at rest identifies hypoperfused myocardium. *Circulation* 2005;111:2943-2950.

Sengupta P, Khandheria B, Korinek J, Jahangir A, Yoshifuku S, Milosevic I, Belohlavek M. Left ventricular isovolumic flow sequence during sinus and paced rhythms: new insights from use of high-resolution Doppler and ultrasonic digital particle imaging velocimetry. *J Am Coll Cardiol* 2007;49:899-908.

Yoshifuku S, Chen S, McMahon E, Korinek J, Yoshikawa A, Ochiai I, Sengupta P, Belohlavek M. Parametric detection and measurement of perfusion defects in attenuated contrast echocardiographic images. *J Ultrasound Med* 2007;26:739-748.

Osranek M, Eisenach JH, Khandheria BK, Chandrasekaran K, Seward JB, Belohlavek M. Arterioventricular coupling and ventricular efficiency after antihypertensive therapy: a noninvasive prospective study. *Hypertension* 2008;51:275-281.

**KRISHNASWAMY  
CHANDRASEKARAN, MD**

Dr Chandrasekaran's research focuses on new imaging techniques (cardiac ultrasound). He is currently developing the Interventional Imaging Service, which combines various imaging techniques with interventional procedures in both the operating room and the cardiac catheterization laboratory. One of the research objectives of this service is to gather noninvasive hemodynamic and imaging data on patients with total artificial hearts and left ventricular assist devices. The effect of these devices on hemodynamic indices obtained by Doppler echocardiography is completely unknown at this time. Dr Chandrasekaran is also involved in research developing applications for intracardiac echocardiography, especially during radiofrequency ablation, and real-time 3-D echocardiography.



**SELECTED PUBLICATIONS**

Yang HS, Sengupta S, Umland MM, Chandrasekaran K, Mookadam F. Primary cardiac angiosarcoma evaluated with contrast two-dimensional and real-time three-dimensional echocardiography. *Eur J Echocardiogr* 2008;9:733-738.

Alharthi M, Mookadam F, Collins J, Chandrasekaran K, Scott L, Tajik AJ. Extracardiac venous heterotaxy syndrome: complete noninvasive diagnosis by multimodality imaging. *Circulation* 2008;117:e498-e503.

Abdelmoneim SS, Bernier M, Bellavia D, Syed IS, Mankad SV, Chandrasekaran K, Pellikka PA, Mulvagh SL. Myocardial contrast echocardiography in biopsy-proven primary cardiac amyloidosis. *Eur J Echocardiogr* 2008;9:338-341.

Yang HS, Srivathsan K, Wissner E, Chandrasekaran K. Real-time 3-dimensional transesophageal echocardiography: novel utility in atrial fibrillation ablation with a prosthetic mitral valve. *Circulation* 2008;117:e304-e305.

Melduni RM, Malouf JF, Chandrasekaran K, Bruce CJ, White RD, Law KK, Al Atawi FO, Somers VK, Gersh BJ, Hodge DO, Friedman PA, Seward JB, Ammash NM. New insights into the predictors of left atrial stunning after successful direct-current cardioversion of atrial fibrillation and flutter. *J Am Soc Echocardiogr* 2008;21:848-854.

## BIJOY K. KHANDHERIA, MD

Dr Khandheria is engaged in research on myocardial mechanics using ultrasound technologies. His work in examining the mechanics of the heart has contributed to advances in the early diagnosis of valvular heart disease. He is examining cardiac vortex action and strength—the interaction between cardiac mechanical function and blood flow patterns inside the heart—as a means of diagnosing early-onset heart disease in diabetic patients compared with those who are not diabetic. His other research interests include cardiac imaging, cerebrovascular disease, transesophageal echocardiography, and aortic valve disease.



### SELECTED PUBLICATIONS

Sengupta PP, Khandheria BK, Korinek J, Wang JW, Belohlavek M. Biphasic tissue Doppler waveforms during isovolumic phases are associated with asynchronous deformation of subendocardial and subepicardial layers. *J Appl Physiol* 2005;99:1104-1111.

Sengupta PP, Khandheria BK, Korinek J, Jahangir A, Seward JB, Belohlavek M. Apex-to-base dispersion in regional timing of left ventricular shortening and lengthening. *J Am Coll Cardiol* 2006;47:163-172.

Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, Whisnant JP, Wiebers DO, Covalt JL, Petterson TM, Christianson TJH, Agmon Y. Patent foramen ovale: innocent or guilty? evidence from a prospective population-based study. *J Am Coll Cardiol* 2006;47:440-445.

Sengupta PP, Khandheria BK, Korinek J, Jahangir A, Yoshifuku S, Milosevic I, Belohlavek M. Left ventricular isovolumic flow sequence during sinus and paced rhythms: new insights from use of high-resolution Doppler and ultrasonic digital particle imaging velocimetry. *J Am Coll Cardiol* 2007;49:899-908.

Sungupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. *Mayo Clin Proc* 2008;83:197-203.

## STEVEN J. LESTER, MD

Dr Lester's interests include the ultrasound evaluation of cardiac structure and function, vascular disease, and prevention. Dr Lester's team tries not to merely define the probability of disease, but rather to dichotomously characterize the presence or absence of disease along with its graded severity. The minor amplitude and temporal subtleties in myocardial and vascular wall motion can be objectively quantified using ultrasound-based myocardial velocity imaging providing a window into the early manifestations of a heterogeneous group of diseases that affect the cardiovascular system. This, in addition to other evolving ultrasound imaging methods, is used to support the aim of Dr Lester's team: to identify subclinical disease much earlier—perhaps decades earlier than current understanding and technology allow—in presumably healthy people so that cardiovascular medicine can evolve from the delivery of medical care (intervention) to the delivery of health care (prevention).



### SELECTED PUBLICATIONS

Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. *J Am Coll Cardiol* 2008;51:679-689.

Lee KS, Honda T, Reuss CS, Zhou Y, Khandheria BK, Lester SJ. Effect of echocardiographic contrast on velocity vector imaging myocardial tracking. *J Am Soc Echocardiogr* 2008;21:818-823.

Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. *J Am Coll Cardiol* 2003;41:1021-1027.



## A. JAMIL TAJIK, MD

Dr Tajik's patient-centered and ever-expanding research programs include adult congenital heart disease; Marfan syndrome; hypertrophic cardiomyopathy and identification of sleep apnea syndrome in high-risk individuals requiring defibrillators; myopericardial disorders (diagnosing and defining longitudinal outcome of restrictive pericarditis); and determining the "golden moment" for surgical intervention in patients with asymptomatic valvular heart disease. Dr Tajik also focuses on advances in cardiovascular imaging, such as using 3-D echocardiography and cardiac CT scanning to examine novel risk factors, establish biomarkers that aid in the early detection of disease, and allow physicians to intervene to either slow or stop disease progression.



### SELECTED PUBLICATIONS

Michelenia HI, Desjardins VA, Avierinos JF, Russo A, Nkomo VT, Sundt TM, Pellikka PA, Tajik AJ, Enriquez-Sarano M. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. *Circulation* 2008;117:2776-2784.

Sengupta PP, Chandrasekaran K, Tajik AJ, Khandheria BK. Twist mechanics of the left ventricle: principles and application. *J Am Coll Cardiol Cardiovasc Imaging* 2008;1:366-376.

Lester SJ, Nishimura RA, Khandheria BK, Tajik AJ, Oh JK, Seward JB. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. *J Am Coll Cardiol* 2008;51:679-689.

Valeti US, Holmes DR, Glockner JF, Ommen SR, Tajik AJ, Schaff HV, Nishimura RA, Araoz PA, Breen JF, Gersh BJ, Rihal CS, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 2007;49:350-357.


Detaint D, Nkomo VT, Tajik AJ, Sarano ME, Sundt TM, Scott CG, Schaff HV. Surgical correction of mitral regurgitation in the elderly: outcomes and recent improvements. *Circulation* 2006;114:265-272.

Binder J, Gersh BJ, Tajik AJ, Ackerman MJ, Ommen SR, Van Driest SL, Nishimura RA. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. *Mayo Clin Proc* 2006;81:459-476.

Attenhofer Jost CH, Danielson GK, Schaff HV, Warnes CA, Puga FJ, Connolly HM, Bailey KR, Shen WK, Seward JB, Tajik AJ. Sinus venous atrial septal defect: long-term postoperative outcome for 115 patients. *Circulation* 2005;112:1953-1958.

## PARTHO P. SENGUPTA, MD

Dr Sengupta's research focuses on the mechanics of the heart and the way in which cardiac motion and blood flow sequence are generated. Redefining cardiac form and function is one of the first steps toward revolutionary approaches in diagnosing and treating patients with heart failure. Future work focuses on the use of high-resolution cardiac ultrasound and new computational algorithms to identify early markers of heart disease without the risk incurred by an invasive procedure. Dr Sengupta's research aims to advance echocardiography as a tool that improves understanding of cardiac mechanical and electrical events occurring at the tissue level—allowing physicians to intervene early with appropriate therapies and preventing physiologic events leading to myocardial dysfunction and congestive heart failure.



### SELECTED PUBLICATIONS

Sengupta PP, Khandheria BK, Korinek J, Wang J, Belohlavek M. Biphasic tissue Doppler waveforms during isovolumic phases are associated with asynchronous deformation of subendocardial and subepicardial layers. *J Appl Physiol* 2005;99:1104-1111.

Sengupta PP, Khandheria BK, Korinek J, Wang J, Jahangir A, Seward JB, Belohlavek M. Apex-to-base dispersion in regional timing of left ventricular shortening and lengthening. *J Am Coll Cardiol* 2006;47:163-172.

Sengupta PP, Korinek J, Belohlavek M, Narula J, Vannan MA, Jahangir A, Khandheria BK. Left ventricular structure and function: basic science for cardiac imaging. *J Am Coll Cardiol* 2006;48:1988-2001.

Sengupta PP, Khandheria BK, Korinek J, Jahangir A, Yoshifuku S, Milosevic I, Belohlavek M. Left ventricular isovolumic flow sequence during sinus and paced rhythms: new insights from use of high-resolution Doppler and ultrasonic digital particle imaging velocimetry. *J Am Coll Cardiol* 2007;49:899-908.

Sengupta PP, Tajik AJ, Chandrasekaran K, Khandheria BK. Twist mechanics of the left ventricle: principles and application. *J Am Coll Cardiol Cardiovasc Imaging* 2008;1:366-376.

## SUSAN WILANSKY, MD

Dr Wilansky's research is focused around the SMART program (Stress Echocardiography in Menopausal Women at Risk of Coronary Disease)—a study of 500 women examining the role of stress echocardiography screening in early menopausal women who have profiles indicating a moderate risk of developing coronary artery disease. SMART will help determine the usefulness of early proactivity in monitoring perimenopausal cardiac risk factors.



### SELECTED PUBLICATIONS

Mesa A, Jessurun C, Hernandez A, Adam K, Brown D, Vaughn WK, Wilansky S. Left ventricular diastolic function in normal human pregnancy. *Circulation* 1999;99:511-517.

Mesa A, Falcone M, Hernandez A, Stainback RF, Wilansky S. Long-term prognosis in women with normal dobutamine stress echocardiography. *Am J Cardiol* 1999;83:1127-1129, A9.

Wilansky S, Moreno CA, Lester SJ. Complications of myocardial infarction. *Crit Care Med* 2007;35(8 Suppl):S348-S354.

Lester SJ, Wilansky S. Endocarditis and associated complications. *Crit Care Med* 2007; 35(8 Suppl):S384-S391.

## FAROUK MOOKADAM, MD

Dr Mookadam's research is focused on the development and effectiveness of individualized medicine. As an example, obesity is becoming an epidemic of increasing proportions in all developing countries, and its metabolic effects damage vascular structures, increasing the risk of cardiac disease. Physicians currently use conventional Framingham risk stratification, which is effective in populations but not useful for individual predictions. Dr Mookadam is researching simple, noninvasive testing strategies—such as arterial function and ultrasound techniques—that can be developed as clinical tools to individualize risk stratification and especially to identify those individual obese patients who may be at increased risk of cardiac disease.



### SELECTED PUBLICATIONS

Jiamsripong P, Mookadam M, Honda T, Khandheria BK, Mookadam F. The metabolic syndrome and cardiovascular disease: part I. *Prev Cardiol* 2008;11:155-161.

Moustafa S, Mookadam F, Cooper L, Adam G, Zehr K, Stulak J, Holmes D. Sinus of Valsalva aneurysms: 47 years of a single center experience and systematic overview of published reports. *Am J Cardiol* 2007;99:1159-1164.

Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. *Lancet* 2006;368:666-678.

Cook DJ, Reeve BK, Griffith LE, Mookadam F, Gibson JC. Multidisciplinary education for oxygen prescription: a continuous quality improvement study. *Arch Intern Med* 1996;156:1797-1801.

## ROBERT L. SCOTT, MD

Dr Scott has research interests in hypertensive heart disease, congestive heart failure in high-risk populations (diabetics, females, African Americans), advanced heart failure treatments, and cardiac transplantation. His research studies include the use of ultrafiltration in both inpatient and outpatient settings to remove extracellular fluid from patients with diastolic or systolic heart failure—a novel technique that has been found to help reduce or prevent hospitalizations. In patients who have had heart transplants, Dr Scott is using genetic profiling techniques and a commercial assay to compile information that may facilitate the weaning of these patients from corticosteroid therapy.



### SELECTED PUBLICATIONS

Noon JP, Trischuk TC, Gaucher SA, Galante SA, Galante S, Scott RL. The effect of age and gender on arterial stiffness in healthy Caucasian Canadians. *J Clin Nurs* 2008;17:2311-2317.

Scott RL. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient. *Cardiol Clin* 2008;26:73-77, vii.

Humphrey JA, Hamming KS, Thacker CM, Scott RL, Sedensky MM, Snutch TP, Morgan PG, Nash HA. A putative cation channel and its novel regulator: cross-species conservation of effects on general anesthesia. *Curr Biol* 2007;17:624-629.

Potluri SP, Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO. Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival in heart transplantation. *J Heart Lung Transplant* 2005;24:1019-1025.




## F. DAVID FORTUIN, MD

Dr Fortuin's research is in the area of gene and cell therapy for ischemic heart disease. Current protocols include a study of the effects of autologous skeletal myoblast transplantation for heart failure after myocardial infarction. Other interests include patent foramen ovale (PFO) closure for cryptogenic stroke. Current protocols include the PFO Access Registry as well as a trial to compare PFO closure with medical treatment for cryptogenic stroke. Dr Fortuin is also involved in multicenter trials studying pharmacologic and catheter-based treatment (coronary stents) of acute coronary syndromes.

### SELECTED PUBLICATIONS

Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Isner JM, Kuntz RE. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 (VEGF2) gene transfer utilizing catheter delivery in patients with chronic myocardial ischemia. *Circulation* 2002;105:2012-2018.

Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ, Schaer GL, March R, Snell RJ, Henry TD, Van Camp J, Lopez JJ, Richenbacher W, Isner JM, Schatz RA. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. *Am J Cardiol* 2003;92:436-439.



## HARI P. CHALIKI, MD

Dr Chaliki's research is in the area of valvular heart disease. It is estimated that 7.5 million patients in the United States are affected by moderate to severe valvular regurgitation and/or stenosis. The inability to identify and treat valvular disease early on leads to death and disability for a large number of patients—a burden that is likely to increase during the next decade as the population ages. Dr Chaliki uses advances in ultrasound technology to improve identification of patients with valvular heart disease who have not yet developed overt signs and symptoms and also uses sophisticated mechanical heart models to study the detrimental effects of valvular stenosis and regurgitation on cardiac function. This research may lead to improved methods of early identification of patients with asymptomatic valvular heart disease so that appropriate treatment methods can be implemented, reducing morbidity and mortality.

### SELECTED PUBLICATIONS

Chaliki HP, Brown ML, Sundt TM, Tajik AJ. Timing of operation in asymptomatic severe aortic stenosis: expert review of cardiovascular therapy. *2007*;5:1065-1071.

Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, Enriquez-Sarano M. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. *Circulation* 2002;106:2687-2693.



## FRANCISCO A. ARABIA, MD

Dr Arabia established both the Heart Transplant Program and the use of mechanical circulatory devices at Mayo Clinic in Arizona. His research interests include cardiomyopathy and corrective and therapeutic procedures, including heart and lung transplant, heart failure surgery, mechanical circulatory support, ventricular assist devices, artificial hearts, and biomedical engineering. Current research protocols include Heartmate II-LVAS: Bridge to transplant and destination therapy arm; Total Artificial Heart (CardioWest); INTERMACS (Interagency Registry of Mechanically Assisted Circulatory Support); and Levitronix (Centrimag)–Failure to wean ventricular device therapy.

### SELECTED PUBLICATIONS

Arabía FA, Tsau PH, Smith RG, Nolan PE, Paramesh V, Bose RK, Woolley DS, Sethi GK, Rhenman BE, Copeland JG. Pediatric bridge to heart transplantation: application of the Berlin Heart, Medos and Thoratec ventricular assist devices. *J Heart Lung Transplant* 2006;25:16-21.

Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, McClellan D, Slepian MJ; CardioWest Total Artificial Heart Investigators. Cardiac replacement with a total artificial heart as a bridge to transplantation. *N Engl J Med* 2004;351:859-867.

Copeland JG, Arabia FA, Tsau PH, Nolan PE, McClellan D, Smith RG, Slepian MJ. Total artificial hearts: bridge to transplantation. *Cardiol Clin* 2003;21:101-113.

Arabia FA, Copeland JG, Smith RG, Banchy M, Foy B, Kormos R, Tector A, Long J, Dembitsky W, Carrier M, Keon W, Pavie A, Duveau D. CardioWest total artificial heart: a retrospective controlled study. *Artif Organs* 1999;23:204-207.

Arabia FA, Smith RG, Rose DS, Arzouman DA, Sethi GK, Copeland JG. Success rates of long-term circulatory assist devices used currently for bridge to heart transplantation. *ASAIO J* 1996;42:M542-M546.



## R. TODD HURST, MD

Dr Hurst's main research interest is the prevention of cardiovascular disease, primarily identifying at-risk individuals before myocardial infarction and stroke occur. His research protocols are focused on identifying parameters of risk, particularly using ultrasound of the carotid arteries, that provide for more effective and individual risk assessment than traditional population-based risk algorithms. Additionally, Dr Hurst is interested in myocardial mechanics with a focus on elite athletes. An active research protocol uses novel echocardiographic parameters such as 2-dimensional strain and strain rate imaging to differentiate the athlete's heart from pathologic cardiomyopathy. He also provides interpretive and advisory support to an ongoing risk evaluation program for retired National Football League players.



### SELECTED PUBLICATIONS

Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, Vargas HE, Appleton CP. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. *Liver Transpl* 2008;14:886-892.

Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. *J Am Soc Echocardiogr* 2008;21:93-111.

Lee HR, Hurst RT, Vargas HE. Transient left ventricular apical ballooning syndrome (Takotsubo cardiomyopathy) following orthotopic liver transplantation. *Liver Transpl* 2007;13:1343-1345.

Jiamsripong P, Honda T, Reuss CS, Hurst RT, Chaliki HP, Grill DE, Schneck SL, Tyler R, Khandheria BK, Lester SJ. Three methods for evaluation of left atrial volume. *Eur J Echocardiogr* 2008;9:351-355.

Reuss CS, Lester SJ, Hurst RT, Askew JW, Nager P, Lusk J, Altemose GT, Tajik AJ. Isolated left ventricular basal ballooning phenotype of transient cardiomyopathy in young women. *Am J Cardiol* 2007;99:1451-1453.

J A C K S O N V I L L E

**F** L O R I D A



## K. L. VENKATACHALAM, MD

Dr Venkatchalam's primary interest is technology translation, especially in cardiac electrophysiology. He managed a team of scientists and engineers in the development of the next generation of wireless pulse oximeters. He also designed the electronic circuitry for the world's first fetal pulse oximeter, a cardiac catheter ablation system, several adult pulse oximeters, an anesthetic agent analyzer, ECG machines, respiration monitors, an ultrasound phased array sonar, digital communication systems, and high-fidelity equipment. His work has led to issuance of 8 patents, and patents are pending on several more inventions.

Dr Venkatchalam is currently working on designs for ablation catheters that will minimize the risk of coagulum formation during electrophysiology procedures. He is also designing a new catheter to map and ablate arrhythmias more accurately and effectively.



### SELECTED PUBLICATIONS

Venkatchalam KL, Garovic VD. Hemodialysis catheter fracture and bacteremia. *Nephrol Dial Transplant* 2003;18:618-619.

Gami AS, Venkatchalam KL, Friedman PA, Asirvatham SJ. Successful ablation of atrial tachycardia in the right coronary cusp of the aortic valve in a patient with atrial fibrillation: what is the substrate. *J Cardiovasc Electrophysiol* 2008 Feb 21. [Epub ahead of print]

Lim B, Venkatchalam KL, Jahangir A, Johnson SB, Asirvatham SJ. Concurrent application of charge using a novel circuit prevents heat-related coagulum formation during radiofrequency ablation. *J Cardiovasc Electrophysiol* 2008;19:843-850.



## FRED M. KUSUMOTO, MD

Dr Kusumoto is Director of Electrophysiology and Pacing at Mayo Clinic Florida. He is interested in the impact of treatment of arrhythmias on patient outcomes, including quality of life and health care resource utilization. The results of his research have been used to develop clinical guidelines for the invasive treatment of supraventricular arrhythmias, including atrial fibrillation. More recently, his research has focused on the techniques, indications, and clinical outcomes of ablation therapy in older patients with atrial fibrillation. In addition to evaluation of clinical outcomes, Dr Kusumoto has studied the usefulness of integrating new technology in the electrophysiology laboratory. He was principal investigator in the recently presented Intracardiac Echocardiography-Guided Cardioversion Helps Interventional Procedures (ICE-CHiP) trial, which considered the use of intracardiac echocardiography during ablation procedures. Dr Kusumoto's other research interest is optimizing implantable cardiac device therapy, particularly postimplant programming and treatment. He has developed noninvasive techniques for determining the optimal atrioventricular delay in patients with hypertrophic cardiomyopathy who are treated with pacing devices.

### SELECTED PUBLICATIONS

Kusumoto FM, Goldschlager N. Cardiac pacing. *N Engl J Med* 1996;334:89-97.

Bathina MN, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto FM. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. *Am J Cardiol* 1998;82:589-593.

Kusumoto FM, Goldschlager N. Device therapy for cardiac arrhythmias. *JAMA* 2002;287:1848-1852.

Goldberg A, Menen M, Mickelsen S, MacIndoe C, Binder M, Nawman R, West G, Kusumoto FM. Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources. *J Interv Card Electrophysiol* 2003;8:59-64.

Kusumoto FM, Goldschlager NF, editors. *Cardiac Pacing for the Clinician*, second edition. New York: Springer; 2008.

## JEFFREY D. HOSENPUD, MD

Dr Hosenpud's research interests focus on immunologic injury, heart transplantation, and heart failure. Early in his career, he developed an animal model of autoimmune myocarditis and was one of the earliest investigators to suggest that immune-derived cytokines could produce myocardial injury and depression of function. Once he became clinically involved in cardiac transplant, he began a basic research program in chronic rejection that manifests as a rapidly progressive coronary artery disease. He has demonstrated that chronic rejection was associated with augmented cell-mediated responses to vascular endothelium, involved both arteries and veins exclusive to the allograft (did not cross the suture line), and coined the term used today "cardiac allograft vasculopathy" as opposed to the previously used "accelerated transplant atherosclerosis" to deemphasize traditional atherosclerotic mechanisms. He was also involved in the earlier studies suggesting a role for cytomegalovirus in this process.

Dr Hosenpud directed the International Heart and Lung Transplant Registries for 8 years and during that time participated in various transplant-related clinical studies. His work first demonstrated that a heart transplant center's volumes impacted outcomes, leading to Medicare's current volume requirements for participation. He also demonstrated that lung transplant in some disease processes does not necessarily impact survival and that survival benefits are directly influenced by underlying disease. This work led to changes in lung allocation from being solely time-on-list-dependent to an algorithm in which underlying disease is a major determinant to priority on the list. Dr Hosenpud more recently has been involved in research in mechanical circulatory support.



### SELECTED PUBLICATIONS

Hosenpud JD, Campbell SM, Mendelson DJ. Interleukin-1 induced myocardial depression in an isolated perfused beating heart preparation. *J Heart Transplant* 1989;8:460-464.

Wagner CR, Morris TE, Shipley GD, Hosenpud JD. Regulation of human aortic endothelial cell-derived mesenchymal growth factors by allogeneic lymphocytes in vitro: a potential mechanism for cardiac allograft vasculopathy. *J Clin Invest* 1993;92:1269-1277.

Hosenpud JD, Breen TJ, Edwards EB, Daily OP, Hunsicker LG. The effect of center volume on cardiac transplant outcome: a report of the United Network for Organ Sharing (UNOS) Scientific Registry. *JAMA* 1994;271:1844-1849.

Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on the survival benefit of lung transplantation for end-stage lung disease. *Lancet* 1998;351:24-27.

Kalya AV, Tector AJ, Crouch JD, Downey FX, McDonald ML, Anderson AJ, Bartoszewski CJ, Hosenpud JD. Comparison of the Novacor and Heartmate Vented Electric left ventricular assist devices in a single institution. *J Heart Lung Transplant* 2005;24:1973-1975.

Hosenpud JD, Greenberg BH, editors. *Congestive Heart Failure: Pathophysiology, Differential Diagnosis and Comprehensive Approach to Therapy*, 3rd edition. Baltimore: Lippincott Williams and Wilkins; 2006.



## JOSEPH L. BLACKSHEAR, MD

Dr Blackshear's principal research interests concern disease mechanisms and optimization of therapeutics in atrial fibrillation and heart failure. He has been principal investigator for a number of important multicenter clinical trials, most notably the Stroke Prevention in Atrial Fibrillation Studies. Current or planned activity includes the response of natriuretic peptides to usual therapeutics and an assessment of the prevalence of acquired von Willebrand syndrome in hypertrophic obstructive cardiomyopathy.

### SELECTED PUBLICATIONS

Blackshear JL, Johnson WD, Odell JA, Baker VS, Howard M, Pearce L, Stone C, Packer DL, Schaff HV. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. *J Am Coll Cardiol* 2003;42:1249-1252.

Blackshear JL. SPAF III Trial of risk stratification and minimum effective warfarin intensity. *Card Electrophysiol Rev* 1998;2:44-48.

The Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. *Lancet* 1996;348:633-638.

Blackshear JL, Kaplan J, Davison C. The neurohumoral profile of Cheyne-Stokes respirations in congestive heart failure is selective elevation of natriuretic peptides. *Circulation* 1999;100(18 Suppl):I.785.

Blackshear JL, Pearce LA, Redfield MM. Is brain natriuretic peptide (BNP) a marker for prognosis in chronic atrial fibrillation (AF)? *Circulation* 1998;98(17S):223I.

## MOHAMAD H. YAMANI, MD

Dr Yamani's special interests are heart failure, heart transplant, and mechanical circulatory support. His research focuses on transplant vasculopathy, rejection of the organ after heart transplant, and the role of adhesion receptors in the pathogenesis of vasculopathy. He has been a principal investigator or coinvestigator on a number of clinical trials, including the EECF Trail in Heart Failure and the WATCH study.

He is studying how angiotensin receptors contribute to the pathogenesis of vasculopathy and rejection by producing inflammation, and his translational research has focused on the role of integrins, tissue factor, and metalloproteinases in heart transplantation. He is also researching the impact of donor brain hemorrhage on transplant outcomes.

He has authored or coauthored numerous articles and abstracts related to his specialty interests and clinical studies, and he has authored chapters related to heart failure in medical textbooks. Dr Yamani serves as a reviewer for journals in the field of heart failure and transplant, and he is a member of the International Society for Heart and Lung Transplantation, the American Society of Heart Failure, the American Heart Association, and the American College of Cardiology.



### SELECTED PUBLICATIONS

Yamani MH, Masri S, Ratliff NB, Bond M, Starling RC, Tuzcu M, McCarthy P, Young JB. The role of vitronectin receptor (alpha $\beta$ 3) and tissue factor in the pathogenesis of transplant vasculopathy. *J Am Coll Cardiol* 2002;39:804-810.

Yamani MH, Tuzcu EM, Starling RC, Ratliff NB, Yu Y, Vince GD, Powell K, Cook D, McCarthy P, Young JB. Myocardial ischemic injury following heart transplantation is associated with upregulation of vitronectin receptor (alpha $\beta$ 3), activation of the matrix metalloproteinase induction system, and subsequent development of coronary vasculopathy. *Circulation* 2002;105:1955-1961.

Yamani MH, Starling RC, Cook DJ, Tuzcu EM, Abdo A, Paul P, Powell K, Ratliff NB, Yu Y, McCarthy PM, Young JB. Donor spontaneous intracerebral hemorrhage is associated with systemic activation of MMP-2 and MMP-9 and subsequent development of coronary vasculopathy in the heart transplant recipient. *Circulation* 2003;108:1724-1728.

Yamani MH, Cook DJ, Tuzcu EM, Abdo A, Paul P, Ratliff NB, Yu Y, Yousufuddin M, Feng J, Hobbs R, Rincon GR, Bott-Silverman C, McCarthy PM, Young JB, Starling RC. Systemic upregulation of angiotensin II type 1 receptor in cardiac donors with spontaneous intracerebral hemorrhage. *Am J Transplant* 2004;4:1097-1102.

Yamani MH, Ratliff NB, Cook DJ, Tuzcu EM, Yu Y, Hobbs R, Rincon G, Bott-Silverman C, Young JB, Smedira N, Starling RC. Peri-transplant ischemic injury is associated with cardiac chimerism and upregulation of stromal cell-derived factor-1 (SDF-1). *J Am Coll Cardiol* 2005;46:1029-1035.

Yamani MH. Chapter 3: Standard medical therapy of heart failure. In: McCarthy P, Young JB, editors. *Heart Failure: A Combined Medical and Surgical Approach*. Malden, Massachusetts: Blackwell Publishing; 2007:21-43.

## THOMAS C. GERBER, MD, PHD

In 2000, Dr Gerber established a cardiac CT and MR imaging program as a collaboration between the Division of Cardiovascular Diseases and the Department of Radiology. The program is recognized nationally and internationally. More than 1,000 cardiac CT or MR examinations are performed there each year.

Dr Gerber is a member of the Board of Directors of the North American Society for Cardiac Imaging and of the Society for Atherosclerosis Imaging and Prevention. He also serves on international committees and on American Heart Association and American College of Cardiology committees that advise on cardiovascular CT and MR imaging.

Dr Gerber has been lead investigator for more than 15 investigator-initiated or multicenter studies, including collaboration with Mayo Clinic in Rochester on research sponsored by the National Institutes of Health. Recently he was among the principal organizers of an international multicenter study of the radiation dose received from coronary CT angiography. He has authored or coauthored more than 30 manuscripts on various aspects of cardiovascular CT and MR imaging. Together with 2 colleagues from Mayo Clinic in Rochester, he has edited a widely recognized 500-page textbook on cardiovascular CT. Dr Gerber's specific research interests include radiation dosimetry and safety, imaging of coronary artery plaque, and quality in imaging, in particular reporting standards, performance measures, and whether cardiac imaging can improve patient outcomes.



### SELECTED PUBLICATIONS


Morin RL, Gerber TC, McCullough CH. Radiation dose in computed tomographic imaging of the heart. *Circulation* 2003;107:917-922.

Gerber TC, Fasseas P, Lennon R, Valeti VU, Breen JF, Berger PB. Clinical safety of magnetic resonance imaging performed early after coronary artery stent placement. *J Am Coll Cardiol* 2003;42:1295-1298.

Kuzo RS, Pooley RA, Crook JE, Heckman MG, Gerber TC. Implications of measurement of blood flow in the superior and inferior venae cavae by magnetic resonance imaging on pulmonary artery opacification during computed tomographic pulmonary angiography. *Am J Radiol* 2007;188:839-842.

Bluemke DA, Achenbach S, Budoff MJ, Gerber TC, Gersh BJ, Hillis DL, Hundley WG, Manning WJ, Printz BF, Stuber M, Woodard PK. Noninvasive coronary artery imaging: MR angiography and multi-detector CT angiography: a scientific statement from the American Heart Association, Subcommittee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Imaging, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young. *Circulation* 2008;118:586-606.





# CONTACT THESE MAYO CLINIC LOCATIONS

## Mayo Clinic, Rochester, Minnesota

### Emergency 24-Hour Number

507-284-2511

### Cardiology Appointments

800-471-1727 (Mon-Fri, 8-5 CT)

507-266-5278 Fax

[www.mayoclinic.org/cardiovascular-rst/appointments.html](http://www.mayoclinic.org/cardiovascular-rst/appointments.html)

### Cardiovascular Surgery Appointments

866-827-8810 (Mon-Fri, 8-5 CT)

507-255-7378 Fax

[www.mayoclinic.org/cardiacsurgery-rst/appointments.html](http://www.mayoclinic.org/cardiacsurgery-rst/appointments.html)

### Pediatric Cardiology Appointments

507-284-9969 (Mon-Fri, 8-5 CT)

507-538-5817 Fax

### Saint Marys Hospital

507-255-2910 Emergency Department (24/7 transfers)

507-255-5123 CCU On-Call Consultant (24/7)

507-255-5123 Cardiovascular Surgery On-Call Consultant (24/7)

507-284-2511 Mayo Clinic Switchboard (24/7)

800-237-6822 Mayo Transport Services (24/7)

*Gold Cross Ground Ambulance, Mayo One Helicopter Service, MedAir Fixed Wing Service*

### Referring Physicians Office

800-533-1564 (24/7)

## Mayo Clinic, Phoenix/Scottsdale, Arizona

### Referring Physicians Office

866-629-6362 or 480-302-6539 (Mon-Fri, 8-5 MT)

**Web Site** [www.mayoclinic.org/medicalprofs-sct/](http://www.mayoclinic.org/medicalprofs-sct/)

## Mayo Clinic, Jacksonville, Florida

### 24-Hour Number

904-953-2000

### Cardiology Appointments

904-953-2475 (Mon-Fri, 8-5 ET)

904-953-2502 Fax

**Web Site** [www.mayoclinic.org/medicalprofs-jax/](http://www.mayoclinic.org/medicalprofs-jax/)

### Referring Physicians Office

800-634-1417 or 904-953-2934 (Mon-Fri, 8-5 ET)

### Web Sites

[www.mayoclinic.org](http://www.mayoclinic.org)  
[mayoresearch.mayo.edu](http://mayoresearch.mayo.edu)

### *Mayo Clinic Cardiovascular Update*

**Medical Editor:** Margaret A. Lloyd, MD

**Surgical Editor:** Christopher G.A. McGregor, MD

**Editorial Board:** David L. Hayes, MD, Hartzell V. Schaff, MD, Frank Cetta, MD, Rick A. Nishimura, MD, Hugh Martin, Marjorie G. Durhman

**Managing Editor:** Jane C. Wiggs, MLA, ELS

**Art Director:** Marjorie G. Durhman

**Photography:** Amanda R. Durhman

Cardiovascular Update is written for physicians and should be relied upon for medical education purposes only. It does not provide a complete overview of the topics covered and should not replace the independent judgment of a physician about the appropriateness or risks of a procedure for a given patient.



200 First Street SW  
Rochester, Minnesota 55905  
[www.mayoclinic.org](http://www.mayoclinic.org)

MC5751-16

© 2008, Mayo Foundation for Medical Education and Research (MFMER).  
All rights reserved. MAYO, MAYO CLINIC and the triple-shield  
Mayo logo are trademarks and service marks of MFMER.